#1CONFIDENTIAL AND PROPRIETARY © Eurofins Scientific (Ireland) Ltd, 2020. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and/or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are not the intended recipient of this document, you are hereby notified that the use, circulation, quoting, or reproducing of this document is strictly prohibited and may be unlawful. Photo images on this page are the copyrighted property of 123RF Limited. Eurofins Corporate Presentation The global leader in food, environment, pharmaceutical & cosmetic product testing and in agroscience Contract Research Organisation services, and an emerging leader in specialised clinical diagnostics Consistently delivering strong, sustainable, profitable growth Doubled revenues every 4 years on average between 2005 and 2020 Sales & reported EBITDA multiplied by more than 23 times between 2005 and 2020 Basic reported EPS to owners multiplied by more than 29 times between 2005 and 2020 www.eurofins.com August 2021 * eurofins Testing for Life#2Disclaimer * eurofins This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever. The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement of Eurofins Scientific's management and involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of research, product/service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation or intention to release publicly any updates or revisions to any forward looking statement or estimate. Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information as "Adjusted Results and Separately Disclosed Items") that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. (Please refer to description of these terms in the Company's Annual Report). The management believes that providing this information enhances investors' understanding of the company's core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. These APMs are described in more detail in the Condensed Interim Consolidated Financial Statements for the period ended 30 June 2021 in Note 1 and in the Consolidated Financial Statements 2020 in Notes 1.27 and 1.28. 2#3Contents ■ Executive Summary ■ Market & Strategic Positioning ▪ Financial review ▪ ESG ■ Outlook ■ Summarised Financial Statements Appendix eurofins 3#4Key operational highlights (1/2) . Record H1 on revenues, profits and cash generation, continuing the positive trends seen in Q1 2021 Strong performance of Core Business¹ with rapidly accelerating, strong growth across business lines: • H1 2021: 17% organic growth² Q2 2021: 25% organic growth³ О Now largely recovered EUR 250m revenues lost due to COVID impacts in FY 2020, earlier than forecast Further notable product launches and continued innovation across business lines, including: * eurofins O Highly innovative rapid testing methods including for the identification of sugars and the certification of organic products New proprietary advanced testing methods to expand Clinical Diagnostics' services for transplant patients Differentiated services/ technologies in Environment Testing including a new automated and robotised PFAS testing method supporting the lowest detection limits globally TruGrafⓇ approved with Humana for in-network coverage of Medicare kidney transplant patients Since H1 2020 was affected by Covid, it is an easy comparable. Looking at organic growth from the pre-pandemic period, H1 2019 is a better indication of long term trends and business recovery Core Business H1 2021 organic revenue growth has been 13% compared to H1 20195 Excluding COVID-19 related clinical testing and reagent revenues 1 2 +16% vs H1 2019, close to +13% corrected for EUR 62m estimated revenue impact of cyber-attack of 2 June 2019 3 +19% vs Q2 2019, close to +13% corrected for EUR 62m estimated revenue impact of cyber-attack of 2 June 2019 4 5 Approved by the International Organization for Standardization (ISO), the European Committee for Standardization (CEN) and the International Dairy Federation (IDF) 2019 corrected for EUR 62m estimated revenue impact of cyber-attack of 2 June 2019 4#5• • Key operational highlights (2/2) * eurofins Alongside the Core Business, the Group remains equally agile, committed and innovative to fight the pandemic Significant contribution from COVID-19 related activities and important milestones reached in H1 2021: Revenue contribution close to EUR 750m O O 25+ million COVID-19 PCR tests completed since the start of the pandemic • ○ 125,000+ SARS-CoV-2 samples sequenced from 23 countries since our press release on 28 December 2020 о Broad network of 1,000+ testing centres developed in Europe to facilitate travelling through SAFER@WORK™ Continued progress made in H1 on the completion of Eurofins' infrastructure and operational excellence programmes, to develop an unrivalled, fully digital network of state-of-the-art laboratories M&A activity: O Very modest level of acquisitions in 2019, 2020 and H1 2021, confirming they are not short-term organic growth drivers 12 acquisitions closed in H1 2021 (EUR 37m full-year equivalent proforma revenues in 2020) ○ ○ EUR 225m committed to date in H2 on 7 acquisitions (EUR 95m full-year equivalent proforma revenues in 2020) O DNA Diagnostics Center, a leader in consumer genetic testing in the U.S., acquired in July 2021, anticipates delivering revenues of USD 55m+ in 2021 O On track to achieve objective of adding EUR 150m proforma revenues from M&A in 2021 5#6FY 2020 Key operational highlights Strong performance and resilience of our core business, despite the impact of multiple lockdowns around the world • Great collaboration across borders and business lines: 。 Exceptionally quick ramp-up in response to the COVID-19 pandemic crisis 。 Significant contribution to public health authorities' fight against the pandemic, helping ensure uninterrupted access to safe food, water, medicines, essential products and services to the public Innovative product launches: 。 SAFER@WORKTM Programmes for employer, environmental surface, site wastewater and product testing 。 COVID-19 RT-PCR tests with easy and reliable at-home self-sampling options 。 GSD NovatypeⓇ RT-PCR for fast variant identification 。 GSD NovaPrimeⓇ SARS-CoV-2, successfully validated for pharynx gargle and saliva samples 。 CE-IVD marked rapid point-of-care finger-prick testing devices to identify past exposure to COVID-19 。 Large Next Generation Sequencing (NGS) capacity and PCR/NGS Primer sets to detect Variants Completing our significant investment programme: 。 Integration of prior acquisitions and finalisation of hub and spoke laboratory network Becoming fully digital o Limited M&A activity eurofins 6#7H1 2021 Key financial highlights Revenue, EUR m 2,323 eurofins Adjusted EBITDA², EUR m Adjusted EBITDA² Margin 3,272 +41% +104% 1,008 30.8% +960bps 21.2% 493 H1 2020 H1 2021 H1 2020 H1 2021 Free Cash Flow to Firm 3, EUR m Net debt/EBITDA4 +55% 489 315 H1 2020 H1 2021 2.5x -1.5x 1.0x H1 2020 H1 2021 H1 2020 Adjusted EPS 5 H1 2021 3.05 +196% 1.03 H1 2020 H1 2021 1 Adjusted results - reflects the ongoing performance of the mature and recurring activities excluding "separately disclosed items" 2 EBITDA - Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions 3 Free Cash Flow to the Firm (FCF-F) - Net cash provided by operating activities, less net capex 4 Leverage - net debt/ PF12M adjusted EBITDA (corrected for the estimated impact of the cyber-attack in 2019) 5 Adjusted EPS - Basic EPS attributable to equity holders of the Company and hybrid capital investors 7#8FY 2020 Key financial highlights Revenue, EUR m 4,563 +19% 5,439 Adjusted EBITDA³, EUR m 1,413 1 931 +52% FY 2019 FY 2020 FY 2019 FY 2020 Free Cash Flow to Firm 4, EUR m Net debt/EBITDA5 162% cash conversion? 873 1 +144% 359 3.2x 1 -1.6x 1.6x FY 2019 FY 2020 FY 2019 FY 2020 * eurofins Adjusted EBITDA³ Margin 1 26.0% 20.4% +560bps FY 2019 Adjusted EPS 5 FY 2020 3.63 1 +107% 1.75 FY 2019 FY 2020 1 Year on year variation - 2020 vs 2019 on reported revenues and FCF-F, on adjusted EBITDA, EBITDA margin and EPS (as defined in footnote 6), comparable (corrected for impact of cyber-attack in 2019) for leverage 2 Adjusted results - reflects the ongoing performance of the mature and recurring activities excluding "separately disclosed items" 3 EBITDA - Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions 4 Free Cash Flow to the Firm (FCF-F) - Net cash provided by operating activities, less Net capex 5 Leverage - net debt/ PF12M adjusted EBITDA (corrected for the estimated impact of the cyber-attack in 2019) 6 Adjusted EPS - Basic EPS attributable to equity holders of the Company 7 Cash conversion ratio - FCFF/ Reported Net Profit 8#9Eurofins' Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis Eurofins provides testing services in four main areas that have a strong impact on human health Environment Food Clinical Pharmaceuticals Founded in 1987 ⚫ IPO on 24 October 1997 at €0.183 * eurofins • Eurofins' share price has multiplied by 527 times since IPO (30% CAGR since IPO as of 30 June 2021 at €96.40) 55,000 employees across network of 1,000 independent companies in over 50 countries operating 900 laboratories Over 200,000 validated analytical methods Over 450 million tests performed each year • COVID-19 testing: 。 Eurofins created global capacity to help over 20 million patients monthly 。 Eurofins global PCR testing capabilities in excess of 150,000 PCR tests daily o Eurofins carried out over 25 million PCR tests in its own laboratories 9#10Drivers for high long-term above GDP market growth * eurofins Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers Increasing wealth and quality of Life Consumer expectations for protection Demand for safe pharmaceuticals, quality food and clean environment Technological progress New analytical methods and lower detection limits New biotech products Advancing globalisation Risks linked to global sourcing and brand vulnerability 1 / 11 Consolidation of the fragmented laboratory market and scale effects Outsourcing of internal laboratories by industry One-stop shopping (focus on few global testing suppliers) 10#11Innovative testing technologies developed in 2020 (1/2) * eurofins • We believe we are uniquely positioned to derive new scientific meaning for years to come. We have: O ✓ Capabilities in Environment, Food, Pharma and Clinical, reinforcing each other ✓ A unique fully digitised hub and spoke laboratory infrastructure ✓ One of the world's largest and most varied proprietary databases (biomarkers, DNA, drugs etc.) ✓ A pool of incredibly talented, motivated employees sharing the same vision, Testing for Life ✓ A decentralised entrepreneurial structure that demonstrates exceptional agility and speed of innovation Laboratories of the Group continued to make advances and innovations in multiple core business areas: BioPharmaceutical Testing Services ✓ Patented process to eliminate donor variability in Antibody-Dependent Cell-Mediated Cytotoxicity assays ✓ OncoPanel™ Cell-Based Profiling Service, with 300+ genomically-diverse human cancer cell lines Eurofins Technologies ✓ World's first AOAC Performance Tested Methods SM status for a screening method to detect aflatoxin M1 in milk commodities 11#12Innovative testing technologies developed in 2020 (2/2) * eurofins o Food and Feed Testing Services: ✓ World's first official method for the identification of fructans certified by the AOAC and ISO bodies ✓ New accredited method for authenticating products containing agave syrup and inulin ✓ Novel full-service support programme for companies entering the "all-natural" infant formula market ○ Environment Testing Services: ✓ World's most sensitive heavy metal detection method in soil, water, food and pharmaceuticals ✓ Ground-breaking Sorbisense TM passive sampling system for ground/ surface water contamination detection ✓ Bespoke microplastic filtration processes and analysis, making testing commercially available o Clinical Diagnostics Testing Services: ✓ Viracor TRACTM, a proprietary donor-derived cell-free DNA assay for detection of acute kidney rejection ✓ TruGraf Liver, a unique, non-invasive blood-based test to support liver transplant patients ✓ TRULO, a multi-centre observational registry study to evaluate post-transplant clinical outcomes in recipients of kidney transplants who are undergoing serial TruGraf testing 12#13Some of Eurofins' Innovations: Becoming Leader in Non- Invasive Prenatal Testing (NIPT) in Europe and Japan eurofins Eurofins is the No. 1 player in the fast growing European NIPT market with ca. 150,000 non-invasive prenatal tests performed per year in 2020 & 2019 vs. ca. 100,000 tests in 2018 Eurofins offer a very comprehensive and innovative portfolio of tests in that market - from trisomy 21 to rare chromosome abnormalities (RCAs) In August 2020, Eurofins acquired GeneTech Inc. and became the market leader in NIPT in Japan 9 different screening options available Option 1 Option 2 Option 3 Option 4 Option 5 Option 6 Option 7 Option 8 Option 9 T21 T13, T18 T9, T16 all other foetal chromosomal anomalies SCA1 22q11.2 micro- deletion 6 micro- deletions 2 9 micro- deletions 3 9 micro- deletions single gene disorders foetal gender 1 Sex Chromosome Anomalies (SCA): Turner-Syndrome, Triple X-Syndrome, Klinefelter-Syndrome, XYY-Syndrome 2 DiGeorge syndrome (22q11.2), 2Cri-du-Chat syndrome (5p15.3), Prader-Willi syndrome (15q11.2), Angelman syndrome (15q11.2) and 1p36 microdeletion, Wolf-Hirschhorn syndrome (4p16.3) 3 include the 6 above plus Jacobsen syndrome (11q23), Langer-Giedion syndrome (8q24.11-q24.13) and Smith-Magenis syndrome (17p11.2) 4 Screens for inherited and de novo single-gene disorders. Inherited genetic disorders screened are: cystic fibrosis, beta-thalassemia, sickle cell anemia and autosomal recessive deafness. De novo disorders screened can cause skeletal dysplasia, cardiac defects, multiple congenital anomalies, autism, epilepsy and/or intellectual disability 13#14Some of Eurofins' Innovations: Onconext - Next Generation Oncology Diagnostics * eurofins • Onconext from Eurofins Genoma is an advanced molecular diagnostics solution for personalised cancer care that uses state of the art technology ① • The team comprises multidisciplinary professionals specialised in molecular biology and genetics NEXT RISK applied to the study of cancer Onconext includes an advanced suite of oncology panels: • Onconext Risk: detects germline mutations involved in genetic predisposition to cancer o Onconext Liquid: analysis of circulating tumor DNA (ctDNA) for cancer detection and monitoring (liquid biopsy) Next Generation Oncology Diagnostics ONTO 。 Onconext Tissue: detects somatic mutations in tumor DNA (tDNA) from tissue samples coming NEXT from traditional biopsies and • Those tests cover many of the most common cancer types including breast, ovarian/uterine, melanoma, colon, gastric, pancreas, prostate, cerebral, renal, pheocromocytoma/paraganglioma • Eurofins Genoma also develops tailor made solutions for its pharma customers and educate oncologists in the clinical utility and use of Onconext in personalized medicine. The ultimate goal of LIQUID Next Generation Oncology Diagnostics ONTO those projects is to make liquid biopsy a reality for patients. An example of this kind of project is the NEXT NGBreast project run in Italy with 80 oncology teams (see www.NGBreast.it) TISSUE Next Generation Oncology Diagnostics 14#15Eurofins is present in several high growth Life Sciences markets critical to fight the COVID-19 pandemic * eurofins Eurofins' position Business line description Oligonucleotides Production and Next Generation Sequencing (NGS) In Vitro Diagnostic (IVD) products #3 worldwide 1 #1 in Europe¹ Start 2000 Start-up Start 2016 Eurofins Genomics' expertise in the synthesis of oligonucleotides has made the company a European market leader and a strong global player with several fully automated production facilities around the world. Eurofins Genomics is also an international leader in Sanger and NGS sequencing services and a growing gene synthesis provider. Eurofins Genomics produces probes, primers and positive controls, key components for RT-PCR testing of SARS-CoV-2, from 6 production sites in U.S., Europe, India and Japan. Whole genome NGS sequencing of the coronavirus supports traceability of the source of outbreaks. Eurofins Technologies' subsidiaries Gold Standard Diagnostics (GSD), NovaTec Immundiagnostica, VIROTECH Diagnostics, Genescan Technologies, Immunolab, Abraxis and Ingenasa offer an innovative suite of IVD instruments, testing kits and testing reagents for laboratories to carry out a large range of clinical diagnostics for infectious diseases (Borrelia, Zika, Chlamydia, CMV, Dengue, etc.). GSD sells IVD instruments and testing reagents to other Eurofins' laboratories and to 3rd party laboratories. Eurofins Technologies has developed a complete range of 1,500 products for industrial and clinical applications including COVID-19 full testing portfolio (RT-PCR, serology/antibodies, antigen rapid tests, Lateral Flow home test/Device (LFD)), from 10 production sites. Listed or larger peers ThermoFisher, GenScript, Swift Biosciences, Merck, Danaher, etc. Roche, Abbott, Becton Dickinson, Hologic, Beckman Coulter, DiaSorin, Biomerieux, Thermo Fisher, Tecan, Idexx, etc. 1 To the best of Eurofins' knowledge, based on data available to the Group 15#16Life Sciences and In Vitro Diagnostic (IVD) products to fight the COVID-19 pandemic (1/2) * eurofins Eurofins Technologies Full range of 1,500+ products/assays produced in 10 sites across 6 countries including 4 in Germany (4), and 2 in the U.S. (2): GSD NovaType III SARS-CoV-2 RT-PCR assay for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 ("India"), B.1.427/B.1.429 ("California/USA"), B.1.351 ("South Africa") and P.1 ("Brazil"). Upgrade of COVID wastewater testing capabilities with variant detection capabilities . Novatype RT-PCR - testing for fast variant identification ○ Detect & ID RT-PCR assay, clinically validated for detecting variants such as B.1.1.7 and B.1.351, with a short turn-around time. We offer accurate and fast PCR kits to help healthcare authorities combat the COVID- 19 pandemic • GeneScan VIRSeek RT-PCR - testing kits and reagents for detection of SARS-CoV-2 in swabs of environmental surfaces о Helps employers evaluate the effectiveness of their sanitation/hygiene measures as they battle COVID-19 CE-IVD marked ELISA serology-based antibody testing kits - antibody testing for IgG, IgM and IgA, results provided in 2 hours о Assays are compatible with many open high-throughput ELISA automation platforms and can therefore provide important cost-efficient testing capacity at scale о ° Eurofins has 5 subsidiaries producing serology kits - Gold Standard Diagnostics, VIROTECH Diagnostics, NovaTec Immundiagnostica, Immunolab and Ingenesa Rapid test: lateral flow device (CE marked) - rapid test to detect total IgG, IgM and IgA antibodies at point-of-care CE-IVD marked Multiplex Real-Time RT-PCR kit - testing kit for the direct, active and qualitative pathogen detection of SARS-CoV-2, providing results in approximately 2 hours Kit demonstrates excellent performance with a 100% Negative and Positive Percent Agreement (NPA, PPA) for all tested samples and no cross-reactivity with other common widely spread coronaviruses Serology tests allow tracking the part of the population infected and may help efforts to develop vaccines and therapies 16#17Life Sciences and In Vitro Diagnostic (IVD) products to fight the COVID-19 pandemic (2/2) * eurofins Eurofins Genomics . Probes, primers and positive controls are key components required for COVID-19 PCR testing • о о Eurofins Genomics is: Certified against ISO 9001, ISO 13485 standards and follows FDA CGMP regulations to produce oligonucleotides used in IVD products One of the top 3 worldwide producers of probes, primers and positive controls, key components for RT-PCR testing of SARS- COV-2 with: " 6 production sites in the U.S., Europe, India and Japan, able to ship plasmid controls within one day (12-18 hours from order receipt) Successful ramp up of capacity of probes, primers and positive controls to meet growing demand NKIN Eurofins Genomics is helping clinical diagnostic manufacturers and laboratories mitigate supply chain disruptions 17#18ELISA high-throughput automation platforms * eurofins Gold Standard Diagnostics (GSD) offers industry-leading ELISA analysers Elisa Assays for Hormones and tumour markers, Veterinary diagnosis and Infectious diseases including qualitative detection of IgG and IgA antibodies to SARS-CoV-2 virus in human serum Low total cost of ownership for instrumentation, consumables, customer support Innovative, industry-leading open platform instruments: ThunderBoltⓇ and the Bolt Thunder Bolt The ThunderBoltⓇ Two-plate, fully automated ELISA+CLIA processor Compact machine, 196 sample capacity Capable of running multiple assays in one single batch The Bolt • BOLT One-plate, fully automated ELISA+CLIA processor Compact machine, 96 sample capacity Customisable, lower throughput, cost-effective design Open platform ELISA instruments are essential as governments and healthcare authorities look to significantly increase COVID-19 testing Open platform ELISA instruments help mitigate supply chain disruptions - allowing users to process a range of testing kits from different manufacturers 18#19Strong Organic Growth in FY 2020 despite COVID-19 disruptions 19.3% organic growth in FY 2020 * eurofins Strong organic growth compared to peers & three large in vitro diagnostic device (IVD) suppliers Peers FY 2020 Organic Growth¹ 25% 2 45% 19.3% Prominent IVD actors FY 2020 Organic Growth* 40.6% 20% 40% 15% 35% 10% 30% 25% 2 5% 19.3% 20% 0% 15% -5% 14.0% 9.5% 10% -10% -6.0% -6.8% -6.5% 5% -15% Eurofins -11.8% Applus 0% Bureau Veritas Intertek SGS Eurofins Abbott (diagnostics) Danaher Roche (diagnostics) 1 Based on public information, using each of the respective companies' Alternative Performance Measures (APM) definitions 2 Organic revenue growth including COVID-19 related clinical testing and reagent revenues and not corrected for the EUR 62m estimated missing revenues from the cyber-attack of 2 June 2019 as disclosed in Annual Report 2020 19#2020% 15% 10% 5% Even excluding COVID-19 clinical testing and reagents, Eurofins organic revenue growth continues to significantly outperform TIC industry peers H1 2020 H1 2021 H1 2021 vs. H1 20192 0%- -5% -10% -15% 3 3 * eurofins CAGR H1 2019-2021 3 3 1 Corrected for EUR 62m estimated missing revenues from the cyber-attack impact of June 2019 2 3 Based on public information, using each of the respective companies' Alternative Performance Measures (APM) definitions, H1 2021 vs. H1 2019 calculated by simple multiplication of the organic growth % for the two periods TICS ex ERF = average organic growth of historic TIC leaders (SGS, Intertek and Bureau Veritas) - Eurofins 1 Average TICS ex ERF 3 -SGS Bureau Veritas Intertek 20#21Fastest growing TIC company which became the leader of an industry with attractive and resilient organic growth eurofins Market Structural growth: est. ~1.5-2.0x Gross Domestic Product growth, globalisation, urbanisation, increasing need and demand for a healthier life and safer environment. Testing is the most efficient and cost effective way to prevent risks (e.g. Clinical Diagnostics tests = 4% of healthcare costs but used in 60% to 70% of medical decisions¹), outsourcing trend Limited cyclicality: A large majority of Eurofins' revenues are recurring, focused on resilient/defensive sectors (testing for life, i.e. testing food, pharmaceuticals, the environment and products that have an impact on our health as well as human clinical testing), diversified industry and geographical exposure In spite of its lower growth routine clinical testing component, Eurofins is outperforming its peers thanks to leadership positions achieved in its chosen less cyclical life science focused markets TICS Organic Revenue Growth² (annual or H1) TICS Organic Revenue Growth 2 (5-year average) Eurofins long term growth gap with TICs is increasing 4 44% 40% 36% 12% +19%6 +150bps 32% 28% 24% 20% 16% 8% 1 | +60% +650bps 6 5 +1,714% +1200bps 3 4% +22%6 +120bps +146%6 +380bps 3 12% 8% +n.s.%6 +680bps 4% 15 I 0% 0% -4% 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 H1 2021 H1 2019 '00-'04 '05-'09 10-'14 15-'19 vs H1 -8% LERF Total OG (FY 2020 & H1 2021) ERF (ex.Covid) TICS ex ERF 2021 -4% 1 Source: Mayo Clinic 2 Source: Eurofins, Company websites TICS ex ERF = SGS, Intertek, Bureau Veritas. Organic revenue growth average if more than 1 year. 3 For 2019 and H1 2021, organic revenue growth corrected for estimated missing revenues of EUR 62m from cyber-attack of 2 June 2019 4 Organic revenue growth of Eurofins Group as a whole (excluding COVID-19 related clinical testing and reagent revenues) 5 Organic revenue growth of Core Business only (excluding COVID-19 related clinical testing and reagent revenues) 6 Eurofins relative organic revenue growth vs average organic revenue growth for TICS (ex ERF) 21 21#22Infrastructure plan update: building a one-of-a-kind hub and spoke laboratories platform for global leadership in our markets to capture scale advantages Building large high throughput laboratory campuses (hubs of the hub and spoke structure) eurofins As of the end of 2020, Eurofins occupied more than 1,400 sites throughout the world (laboratories, offices, phlebotomy sites, storage/warehouses, etc.). The total net floor area of these sites amounted to about 1.4 million m², of which more than 1.2 million m is laboratory space. 2017 +53,000m² Nantes, FR ext. Livingston, UK Madrid, ES Ho Chi Minh City, VN Gurgaon, IN Bangalore, IN Lancaster, PA ext. Hangzhou, CN Dayton, NJ Hasselt, BE 2018 +64,000m² Suzhou, CN Taipei, TW Wolverhampton, UK ext. Planegg, DE ext. Dungarvan, IE ext. Melbourne, AU Fresno, CA Wesseling, DE ext. Bangalore, IN Katowice, PL 2019 +65,000m² Vienna, AT ext Shanghai, CN Guangzhou, CN Hamburg, DE ext. Heerenveen, NL Bucharest, RO Santa Clara, US Lancaster, US ext. Madison, US Pasadena, US 2021-2022 +83,500m² planned 2020 +35,000m² Lenexa, US Tustin, US Shanghai, CN Girraween, AU Aix-en-Provence, FR Taichung City, TW Gunpo, KR Llanera, ES Barcelona, ES Murcia, ES Welshpool, AU Lodz, PL Guangzhou, CN Feltham, UK Leola, US Castellon, ES Cork, IE Mississauga, CA Heerenveen, NL. San Diego, US Glostrup, DK Saverne, FR Tallinn, EE Lidkoping, SE Lentilly, FR Brugge, BE Bron, FR Les Ulis, FR Consolidating inefficient smaller sites into large high throughput campuses Separately disclosed items (SDIs) related to one-off costs and temporary/non-recurring losses (ie. integration, reorganisation, network expansion, start-ups) should decrease gradually. Values at Full Year SDIS SDIs/adjusted EBITDA 2016 €18.5m 3.9% 2017 €43.5m 7.8% 2018 €68.4m 9.5% 2019 €97.8m 10.5% 2020 €61.8m 4.4% Start-up labs opened in high-growth markets where acquisition prices are too high and/or acquisition options are limited 2016 22 2017 30 2018 15 2019 15 Investments in developing state of the art bespoke IT solutions Total spend on new generation standardized tool 2016 €35m + Opex 2017 €32m + Opex 2020 Beyond 2020 18 More limited, focusing mainly on Asia Pacific 2018 2019 2020 €33m + Opex €32m + Opex €36m + Opex Beyond 2020 Target <€30m p.a. Beyond 2020 Investing to be the most digital TIC company 22 22#23Revenues (Em) Start-ups an increasingly attractive investment as we leverage our scale and experience * eurofins 178 laboratories start-ups between 2000 and 2020 Substantial acceleration offers tremendous growth potential 1) Acceleration in laboratories start-up programmes 500 450 Where we are building start-up labs 400 350 North America 33 Rest of World 73 Europe 72 300 25 start-ups 2000-2009 (Programme 1) • 18 start-ups 2010-2013 (Programme 2) • 102 start-ups 2014-2018 • 15 start-ups opened in FY 2019 250 200 150 100 • 18 start-ups opened in FY 2020 These 178 start-ups continued to contribute to the overall organic growth of the Group, accounting for 3.2% out of the 19.3% organic growth achieved in FY 2020 2) Commitment to invest for future growth • • • Eurofins start-up programme represents a significant investment for the future and has a short- term dilutive impact on the Group's margins and cash flows. On average, start-up periods last for 2 to 3 years in mature markets and 2 to 5 years in emerging markets in order to reach breakeven before they become profitable The EBITDA margin from our two most recent programmes (2010-2013 and 2014-2020) improved significantly to reach levels in the mid-teens, but this is heavily influenced by the ability of our start-up clinical laboratories to contribute to the fight against COVID-19 by facilitating access to SARS-CoV2 tests. 50 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 25 start-ups 18 start-ups 135 start-ups Programme 1 (2000-2009) Programme 2 (2010-2013) Programme 3 (2014-2020) 3) Start-up investments complement our acquisition strategy • Alternative strategy in high-growth markets and emerging markets where acquisition prices are too high and/or there are limited viable options for acquisitions *2019 revenues are corrected for the estimated cyber-attack impact 23#24Eurofins is experienced in successfully integrating acquisitions and is returning to its historic M&A run rate . * eurofins M&A has always been an integral part of Eurofins long-term strategy to build a unique bioanalytical testing platform for global leadership in its attractive high growth and very scalable markets From its IPO (Oct. 1997 to H1 2021 Eurofins has completed 411 acquisitions to consolidate the bioanalytical testing market, build leadership positions in its markets, expand its portfolio of testing methods and customers, generate economies of scale and create barriers to entry. Since 1 July 2021, Eurofins has completed 7 acquisitions including the acquisition of DNA Diagnostics Center ("DDC"). 2017 and 2018 were two exceptional years of M&A activity as unique opportunities became available during that time, including EAG Laboratories, Covance Food Solutions and TestAmerica Since 2019, Eurofins reverted back to its normal M&A activity. In the coming years the Group will focus more on operational excellence than M&A since the most strategic acquisitions have already been completed and the laboratory network in the U.S. for Food and Environment Testing is now largely completed Average number of acquisitions 60 50 40 30 127 347 56 235 per year 10 18 10 per year per year 0 IPO-2010 2011-2016 2017-2018 373 26 26 2019 399 2020 450 411 400 350 300 250 200 150 100 12 50 0 H1 2021 Cumulative number of acquisitions Average number of acquisitions completed Cumulative number of acquisitions completed Eurofins has a long track record of acquiring and successfully integrating acquired businesses 24#25Exceptional Business Performance Strong revenue growth Revenues (€m) 6,000 5,000 4,000 3,000 2,000 Doubled in 3 years versus 5-year objective €1.04bn in 2012 to €1.95bn in 2015 +23.2% 3YR (2012-2015) CAGR 1,000 €1.41bn €1.23bn €1.04bn Illustration of Eurofins' historical revenue growth €1.95bn Doubling in 3 years versus 5-year objective €1.95bn in 2015 to €3.78bn in 2018 +24.7% 3YR (2015-2018) CAGR €2.54bn €2.97bn €3.78bn * eurofins +19.9% 2YR (2018-2020) CAGR €4.56bn 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 €5.44bn 25#26• • Eurofins at the forefront of innovation with new COVID-19 related developments * eurofins • Two important milestones reached: • ○ 25m+ COVID-19 PCR tests completed since the start of the pandemic О 125,000+ SARS-CoV-2 samples from 23 countries sequenced since its press release on 28th December 2020 announcing the launch of a new ARTIC Next Generation Sequencing (NGS) service Clinical Enterprise awarded U.S. Government agreement¹ to provide national COVID-19 testing opportunities to 24m+ people in K-8 schools, underserved populations and congregate settings such as homeless shelters Eurofins Viracor launched new tests, including COVID-19 SARS-CoV-2 inSIGHT TM T Cell Immunity Testing to support healthcare providers with the supply of critical insights to aid in treatment decisions Eurofins Genomics launched SynPure Linear Polyacrylamide for COVID testing and other research and development applications Eurofins Technologies continued to develop diagnostic solutions for COVID-19, particularly in response to emerging mutations: GSD NovaType III SARS-CoV-2 RT-PCR assay for the rapid, one-step detection of SARS-CoV-2 Variants of Concern о Upgrade of COVID wastewater testing capabilities with variant detection capabilities EmpowerDX direct-to-consumer, FDA-authorised COVID-19 Home Collection PCR kit were launched on Amazon U.S. and in all Rite Aid stores across 17 states in the U.S. EmpowerDX first to receive FDA-emergency use authorization for its at-home nasal PCR test for children three years and older 1 Agreement available at https://www.defense.gov/Newsroom/Releases/Release/Article/2633565/memorandum-of-understanding-for-acquisition-support-signed-between-the-departme/ eurofins eurofins 26#27SAFER@WORK™ update • . • * eurofins Through its SAFER@WORK TM programmes, Eurofins continues to help businesses maintain or re-start operations and to enable safe and secure travel and leisure Over 3,250 SAFER@WORK TM contracts signed or in final stages across 36 countries (as of June 2021) Eurofins COVID-19 sentinel™ Eurofins developed a broad network of testing centres to facilitate summer travelling, including: О Around 1,000 testing centres across Europe covering major travelling hubs and providing testing accessibility in a broad variety of locations WASTEWATER TESTING WORN MASK TESTING SURFACE INDOOR AIR TESTING TESTING Mobile testing centres in France, Belgium and Germany to process PCR tests Network supported by intuitive web-portal¹ where travelers can book appointments and access their testing information • Further partnerships signed, including with: ○ Several cruise lines Hotel Groups, to provide their guests with access to convenient and affordable PCR testing • من Staff PCR Testing AIA Consulting Services E Staff Antibody Testing Environmental Surfaces PCR Testing Wastewater Testing Product Testing О Airports and private jet operators, to offer exceptional level of safety to passengers As previously outlined, revenues from these contracts are dependent on employees coming back to work and travel and leisure activities recommencing and are expected to be delivered in H2 2021 SAFER@WORK™ Comprehensive solutions to keep your staff and customers safer during the COVID-19 pandemic 1 Available at https://www.eurofins.com/covid19-travel-regulations-testing-stations/ 27 27#28COVID-19 Test Strategy to help the return to normality * eurofins U.S. based example: SENTINEL TESTING AIR WASTEWATER SURFACE POOLED POSITIVE RESULT PCR 5/1 BASELINE PCR WORN MASK + POOLED MASK PCR POOLING ONGOING SYMPTOM TRACKING LOCAL INFECTIVITY RATES MONITORING ONGOING ANTIBODY TESTING TO MONITOR EXPOSURE NEGATIVE INDIVIDUAL TESTING PCR MEDICAL PERSONNEL OBSERVED Isolation based on CDC guidance (for individual PCR or POC antigen) PSWAB SALIVA NASAL SWAB POSITIVE POSITIVE PCR SELF-COLLECTION (AT HOME) NASALSAB PCR MEDICAL PERSONNEL OBSERVED (POINT OF CARE - POC) NASAL SWA NEGATIVE Retest every 2-3 days, during exposure risk period. Keep performing sentinel testing in tandem. Key Highlights Developed a comprehensive offering to fight COVID-19 Developed solutions for the detection of SARS-CoV-2 on environmental surfaces • Eurofins was the first commercial European laboratory to receive an EUA for an at-home nasal PCR test for young children EmpowerDX At-Home COVID-19 Nasal PCR and gargling self-collection kits are painless and provide online results within 24h Safer@WorkTM can support a multifaceted view on infection vectors and will likely play a critical role as companies start looking to enable their employees to get back to their workplace safely 28#29Contents eurofins ■ Executive Summary ■ Market & Strategic Positioning: Overview of Markets Served & Structure ■Financial review - ESG ■ Outlook ■ Summarised Financial Statements ▪ Appendix 29 29#30Leading global and local market positions in attractive high-growth markets* (1/2) eurofins Eurofins position Total market size estimate* Testing for Pharma/Biotech/Agrosciences N°1 to N°3* worldwide Start 2000-2005 - € 6bn Food & Feed Testing Environment Testing N°1* worldwide Start 1987 ~ € 4bn N°1* worldwide Start 2000 - € 5bn Clinical Diagnostics Start-Up Start 2014 € 312bn** by 2025 Eurofins' focus Genomics/ Esoteric Testing: € 5- 10bn* Segment description Key clients Full range of laboratory services for biopharmaceutical product development, quality testing, discovery and pharmacology services, genomic sequencing and genotyping as well as phase I-IV clinical research programs More than 90% of top 20 largest global pharma companies are customers Ensuring food quality and preventing contamination and foodborne illnesses caused by pathogens and other harmful substances. Expertise includes a.o. testing for dioxins and organic contaminants, pesticides, mycotoxins, allergens, authenticity, pathogens and vitamin The largest global food and beverage producers are clients Analysis of drinking water, groundwater, seawater, soil, sediment, air, etc; using analytical methods to assess their purity/absence of polution and impact on health and the environment Industrial companies, water plants, local councils, construction companies, etc. Biological samples (blood, urine, etc.) analysis to diagnose diseases and aid in medical decisions Doctors, hospitals, health insurers, patients Listed peers or large peers Pharmaceutical Product Development (PPD), ICON, Charles River, IQVIA, LabCorp/Covance, Wuxi, Evotec etc. SGS, Bureau Veritas, Intertek, etc. *Only includes the outsourced part of the market. Estimate to the best of Eurofins' knowledge, based on data available to the Group **Global Market Insights, August 20, 2019 (2025 market size estimate of USD 350bn converted at 31/12/2019 USD/EUR exchange rate of 0.89) ALS, SGS, Bureau Veritas, Idexx, etc. Guardant Health, CareDx, Natera, Exact Sciences, Myriad Genetics, NeoGenomics, Invitae, Genomic Health, Foundation Medicine, LabCorp, Quest, Sonic Healthcare, Synlab, Unilabs, Cerba, etc. 30 30#31Leading global and local market positions in attractive high-growth markets* (2/2) eurofins Eurofins position Testing for Pharma/Biotech/Agrosciences N°1 to N°3* worldwide Start 2000-2005 Total market size estimate* ~ € 6bn Food & Feed Testing Environment Testing N 1 worldwide N°1* worldwide Start 1987 ~ € 4bn N 1 Worldwide N°1* worldwide Start 2000 ~ € 5bn Clinical Diagnostics Start-Up Start 2014 € 312bn** by 2025 Eurofins' focus Genomics/ Esoteric Testing: € 5-10bn* Eurofins ranking N 1 Worldwide in Pharma Products Testing N 1 Worldwide in Discovery Pharmacology Services N 1 Worldwide in Agroscience CRO services Among top 5 global providers of central laboratory and genomic services N 1 or 2 in most segments/ countries in Europe and the USA N 1 in the USA N 1 in Europe N 1 in Germany N 1 in France N 1 in Nordics/Scandinavia N 1 in Benelux N 1 in the UK & Ireland N 1 in Spain N 1 in Brazil N 1 in Agro Testing EU N 1 in the USA N 1 in Europe N 1 in Germany N 1 in France N 1 in Nordics/Scandinavia N 1 in Ireland N 1 in Benelux N 1 in Taiwan N 2 in Spain N 2 in Japan Establishing leadership in targeted higher- niche growth innovative areas (e.g. genomics, infectious diseases, etc.) of the clinical testing market, mainly in the U.S. and Europe, as well as market access through local laboratories in many large markets worldwide to distribute advanced tests. *Only includes the outsourced part of the market. Estimate to the best of Eurofins' knowledge, based on data available to the Group **Global Market Insights, August 20, 2019 (2025 market size estimate of USD 350bn converted at 31/12/2019 USD/EUR exchange rate of 0.89) 31#32U.S. Other listed peers peers Eurofins Pharma Services in more detail Spanning the entire drug development cycle eurofins Genomics Sequencing Oligonucleotides Pharmacogenomics Transcriptomics Genotyping SNP-analysis IDT/Danaher, Genewiz/Brooks Discovery Pharmacology High-throughput- screening Molecular- Pharmacology Cell-based Assays In Vitro Screening In Vitro Profiling In Vivo Safety In Vivo efficacy Charles River Pre-clinical/ Early Development Pharmacology Bioanalytical Analysis Translational Medicine Phase I Studies Catalent, Charles River, ICON, IQVIA, LabCorp, Syneos Health, PPD Clinical (Central Laboratory/ Bioanalytical) Biomarkers Bioanalysis Immunogenicity Proteomics Microbiological and Anti- infective analysis Bioavailability Bioequivalence Charles River, ICON, IQVIA, LabCorp, Quest, Syneos Health, PPD Development & Manufacturing (CDMO) Complex API Development Multi-Step Synthesis Cytotoxic and Highly Potent DS and DP Manufacturing Catalent, Charles River BioPharma Products Testing Pharmaceuticals, Biologics, Medical Device: Safety, Characterization, Quality Control, Process Development Hygiene Monitoring Packaging Charles River, PPD Abcam, etc. Evotec, Abcam, Albany Molecular Research, etc. Evotec, Parexel, etc. Albany Molecular Research, etc. Albany Molecular Research, Lonza, Cambrex etc. SGS, Wu Xi App Tec, etc. 32 32#33= Building leadership positions in an industry with significant network effects and competitive advantage for the market leader eurofins • High barriers to entry High level of investment and innovation required to build and efficiently run a network of modern laboratories (buildings, equipment, IT infrastructure and solutions, talent) • Clients seldom change laboratory supplier (high switching costs) • Clients increasingly expect a complete range of tests at very short turnaround times (TATS) Reinforcing leadership positions Scale matters K • • Generating synergies . • • • Unique ability to offer our clients access to a portfolio of over 200,000 different tests across more than 50 countries thanks to state-of-the-art global laboratory network Scale & volume required for short TATS on complex tests Unique ability to offer one-stop shops to our clients thanks to advanced bespoke IT solutions Hub and spoke model to generate scale for complex tests Network effect/cross-selling synergies Site specialization drives cost synergies (efficiency - each method requires heavy investment and thus needs to be amortized over large volumes, purchasing power) Innovation/R&D synergies We have been building a hard to replicate laboratory platform Some competitors who tried to diversify into our sector are starting to exit some of our markets (LabCorp, Exova, TÜV Rheinland, Applus etc.). Smaller/mid-size players lose market share 333#34Building a unique platform for global leadership in our attractive high growth markets with large network effects * eurofins High barriers to entry exist in Eurofins' markets. Significant investments are required to build and efficiently run modern laboratories. Clients seldom change laboratory supplier. Constant scientific breakthroughs lead to novel equipment and testing methods. Methods often take years to be developed and validated Clients increasingly expect a complete range of tests - Food testing is over 130,000 validated tests already. Stickiness of business. Switching costs are high. Clients often have decade-long stable relationships with their laboratory of choice. Bioanalytical testing is a highly scalable activity Economies of scale in testing and logistics are huge and create a large cost advantage for the market leader vs. competitors. In order to unlock economies of scope and scale, a global standardized network of laboratories is needed • Developing a state-of-the-art global laboratory network takes decades and requires very large investments: Advanced bespoke IT solutions are required to offer a one-stop-shop for clients around the globe providing them access to the full range of services offered by all laboratories in the network Automation, artificial intelligence (AI) and proprietary reagents and methods are very expensive and these investments require large scale to be justified. Eurofins' 2020 growth plan, aimed at building a leading one of a kind global laboratories platform in its chosen high growth markets, is well underway For over 15 years, Eurofins has been consistently investing more than its peers to develop a hard-to-replicate network of laboratories and a very broad portfolio of advanced bio-analytical tests and more non time critical tests to its large hub labs. These large investments, aimed at long-term value creation, impact Eurofins' short term cash flow generation and margins Between 2010 and 2020, Eurofins developed one-of-a-kind 'hub and spoke' laboratory infrastructure for its leading markets by consolidating less efficient and smaller sites into large, high-throughput Centres of Excellence (or 'hubs'), in order to unlock the potential of economies of scale and the large cost advantage available to the market leader vs. competitors. Eurofins has invested much more than its peers in its unique network of laboratories and state-of-the-art IT solutions, putting its growth plan to develop market leadership platform well into motion. Looking beyond 2020, when Eurofins' five-year growth phase will have completed in 2021, the Group believes it will be well placed to leverage these market leadership positions, in combination with its global network of laboratories, scale and scientific excellence, to significantly improve its cash flow generation and profitability to create further significant value. 34#35Since 2015, Eurofins has built a one of a kind hub and spoke laboratories infrastructure platform in the U.S. Food testing market - Hub and spoke model allows for cost-effective and timely delivery of high quality testing results eurofins Eurofins is structuring its unique network of laboratories using the hub and spoke model embraced by the largest global logistics companies: • Centralise complex chemistry and molecular testing at large hub laboratories Carry out time critical microbiology testing and sample collection/courier routes at/around smaller satellite local (spoke) laboratories A Des Moines, IA Madison, WI Indianapolis, IN New Orleans, LA = = Chemistry hub/campus = Specialty laboratory (Milk or Nutraceuticals) = Microbiology laboratory 35#36Building the Platform - Eurofins 2012 - Eurofins 2020 * eurofins 2012 2015 2019 2020 2012-2020 A +8 years Revenues (€ m) 1,044 1,950 4,563 5,439 23% CAGR Employees 10,890 18,382 43,320 50,000 21% CAGR (average FTE) Number of laboratories 170 225 >800 >800 Over 4x (year-end) Number of countries 34 39 >50 >50 >16 Number of business lines with global leadership 4 (Food and feed, Environment, BioPharma product testing, Drug discovery services) Number of future 1 (Genomics) oriented business lines 4 (Food and feed, Environment, 7 (Food and feed, Environment, BioPharma product testing, Drug discovery services, Agroscience CRO services, testing, Drug discovery Specialised Material Sciences BioPharma product services) 2 (Genomics, Clinical Genetics) testing, Cosmetics Testing) 5 (Genomics (#2 globally), Forensics (#1 in Europe), Clinical Genetics, Pharma CDMO, Eurofins Technologies) 7 (Food and feed, Environment, BioPharma product testing, Drug discovery services, Agroscience CRO services, Specialised Material Sciences testing, Cosmetics Testing) 5 (Genomics (#2 globally), Forensics (#1 in Europe), Clinical Genetics, Pharma CDMO, Eurofins Technologies) +3 +4 36#37eurofins Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters New Markets Denmark: Food and Environment Testing 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sweden, Norway: Food and Environment Testing Global: BioPharma Product Testing France Environment Testing Brazil: Food Testing Europe: Agro Testing Global: Discovery Pharmacology Laboratory Services Australia, New Zealand: Food & Environment Testing UK & Ireland: Food Testing Austria: Environment Testing France: Specialized Clinical Diagnostics Europe: Forensics Testing Global: Genomic Services Global: Agroscience CRO Services Finland: Environment Testing USA: Specialized Material Sciences Testing USA: Food Testing France: BioPharma Product Testing X No No 1 No 1 No 1 No 1 No 1 No 1 No 2 No 1 000 000 No 1 00000* No 1 No 1 Germany: BioPharma Product Testing USA: Environment Testing Spain: Food Testing Global: Cosmetics Testing Netherlands: BioPharma Product Testing Ireland: Environment Testing No 1 1 00000000* No No No 1 = Market Entry Spain: Environment Testing Japan: Genomics Japan: Environment Testing Japan: Non-Invasive Prenatal Testing Taiwan: Environment Testing No 2 0000 Eurofins already has long-standing N°1 or N°2 positions in its historic markets, Europe and North America, across its major business lines: Food, Environment, BioPharma, Agroscience, Genomics, Forensics *To the best of Eurofins' knowledge, based on data available to the Group 37#38Overall, a large majority of Eurofins' revenues come from markets where the Group has established global leadership positions Business Line Food & Feed testing Environment testing Clinical Diagnostics BioPharma Product Testing (BPT) Consumer Product Testing Early Development & Central Laboratory Agroscience CRO Services Specialised Materials Science testing Discovery Pharmacology Laboratory Services Genomics & Forensics Technology Services Cosmetic Product Testing Total % of 2020 proforma revenues by business lines with global leadership positions* * eurofins Global leadership position 70% These global leadership positions are the basis to create high barriers to entry, significant network effects and competitive advantage for Eurofins *Excluding COVID testing 38#39Eurofins is already present in countries generating over 86% of the world's GDP... but still has lots of room to grow Eurofins market presence * eurofins International Monetary Fund (Estimates as of July 2021) GDP ($tn) % of world's GDP Eurofins presence (To the best of Eurofins' knowledge, based on data available to the Group) Food testing Biopharma services Environment testing Clinical Diagnostics #1 #1 #1 #1* Country EU USA China Japan Germany UK 22.7 24.2% 16.6 17.7% 5.4 5.7% 4.3. 4.6% 3.1 3.3% India 3.1 3.2% France 2.9 3.1% Italy 2.1 2.2% Canada 1.9 2.0% South Korea 1.8 1.9% Russia 1.7 1.8% Australia 1.6. 1.7% Brazil 1.5 1.6% Spain 1.5 1.6% Mexico 1.2 1.3% Indonesia 1.2. 1.2% Netherlands 1.0 1.1% Switzerland 0.8. 0.9% Saudi Arabia 0.8 0.9% Turkey 0.8 0.8% Taiwan 0.8 0.8% Iran 0.7 0.7% Poland 0.6 0.7% Sweden 0.6 0.7% Belgium 0.6 0.6% Total top 25 79.3 84.5% 20 Eurofins present in 20 countries of 73.7 78.6% world's top 25: + other countries 7.7 8.2% Eurofins present in more than 50 81.5 86.8% countries: #1 #1 #31 ✓ #1 #1 _nnvv nnvmvvv vmn ༨༨༨༩ #1 vnv 20 #1 - Eurofins is market leader * = in BioPharma Products Testing (BPT) ** = in Specialized Clinical Testing #1/2 #231 ཟླ་ ཟླ་ ༨ ༨ ཟླ ༨ ༨ ཟླཅུ་ ཟླཟླ #1 #1** #1* ✓ #1* #1* 14 #1 #1 ✓ #1 v mm 17 #1 #1 #1 ✓ 16 11 ...and penetrates the world's Top 25 economies with more and more of its services! 39#401987 - H1 2021: In only 33 years we built a unique global network eurofins From 1 laboratory in Nantes (France) in 1987 to 900 laboratories around the world in 2021! From 4 employees in 1987 to 55,000 in July 2021! Now operating in over 50 countries! 12,538 employees 31,111 554 laboratories employees 184 laboratories North America Europe 100 laboratories Asia 7 Pacific Africa South America 3 laboratories 15 979 employees 6,830 employees laboratories Eurofins' site map at 31 December 2020 40 40#41Global trends in regulation support the business * eurofins Strongly regulated markets (EU, U.S.) are still amending and adding regulations • Eastern European countries catching up with EU regulations • Fast development of regulation in Asia • • Regulation used for support of trading blocks (e.g. EU, NAFTA, ASEAN) Major pieces of legislation European Food Regulation (EC) 178/2002 • U.S. increasing government evaluations of organ procurement organizations aimed at increasing the number of organ transplants ⚫ EU new regulations on testing medical devices • European REACH directive • U.S. Country of Origin Labelling (COOL) law • PRC Food Safety Law in China • Food Safety Modernization Act (FSMA) in the U.S. • Comprehensive Review of Food Labelling Law and Policy in Australia & New Zealand • • • Key areas of food regulation More stringent regulations around per- and polyfluoroalkyl substances (PFAS) Food imports Labelling (e.g. allergen, origin label, reference intakes) • Foodstuffs (marketing standards for beverages, meat, fish, dairy products) • Pesticides • GMO & GM products • Additives (vitamin & mineral fortification, flavourings, sweeteners, enzymes) 41#42Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins Company MML Alrijne Labser Axéréal & Terrena Signify Astellas Danish Hydrology Inst. Suez/Sita Danish farmers association Lyon University Hospital Austrian Research Institute Clermont University Raisio Group Mondi DLG Group Miljølaboratoriet BASF/QTA MWH Global TÜV SÜD Cranswick plc Danone = Food and feed - Environment Outsourced Activity Clinical Diagnostics Food and Feed testing Galys agricultural laboratories Materials Analysis and Reliability Astellas Analytical Science Labs Official water reference lab Envirolab Steins' water/environment laboratory Phase I Activity * eurofins Country Netherlands Spain France The Netherlands Japan Scandinavia The Netherlands Denmark France Food testing Austria Mineral water analysis France Food product testing Finland Environmental, paper/pulp testing Slovakia Food and feed producer Denmark Environmental testing network Denmark Environmental, chemicals U.S. U.S. Environmental, water-testing Dioxin Analysis Food testing Infant and clinical nutrition analysis BioPharma Germany UK Germany = Specialised Material Sciences = Clinical Diagnostics 42#43Meaningful industry consolidation is underway Date Company November Synlab Analytics & Services November LGC July Genomic Health July Quotient Sciences July Just Biotherapeutics April Paragon September Genewiz July Halo March BIO7 March Selection of recent significant transactions in the testing industry Acquirer Geography Sales (Em) EV (Em) EV/Sales (x) EV/EBITDA (x) 2020 SGS EU Integrated DNA Technologies Inc. September Chiltern International June May April EUROIMMUN Patheon Exova January Cerba December Unilabs November Cepheid January WIL Research 202 550 2.7x 16.2x AVERAGE 2.7x 16.2x 2019 Cinven and Astorg UK 525 3,519 6.7x 17.1x Exact Sciences US 507 2,816 5.6x 25.0x Permira UK 129 705 5.5x 17.0x Evotec US 18 80 4.5x N/A Catalent US 178 1,067 6.0x 21.4x AVERAGE 5.7x 20.1x 2018 Brooks Automation US 102. 383 3.8x N/A Cambrex US 87 353 4.0x 15.7x Cerbal FR 110 500 4.5x N/A Danaher Corp US 163 1,628 10.0x N/A AVERAGE 5.6x 15.7x 2017 Labcorp US 133 990 7.4x N/A PerkinElmer DE 166 1,139 6.9x 32.0x Thermo Fischer NL 1,712 6,424 3.8x 18.1x Element Materials Tech UK 401 743 1.9x 9.4x PSP, Partners Group FR 630 1,800 2.9x 12.0x AVERAGE 4.6x 17.9x 2016 Apax IX Danaher CHI 675 1,500 2.2x 11.8x US 485 3,770 7.8x N/A Charles River US 194 527 2.7x 13.0x AVERAGE 4.2x 12.4x 2015 December Element Materials Technology Bridgepoint UK 270 900 3.3x 12.2x December LGC KKR UK 358 1,237 3.5x 14.2x October July Professional Service Industries (PSI) Amedes Intertek US 227 290 1.3x 7.6x Antin Infrastructure Partners DE 399 775 1.9x 9.7x June Environmental Resources Mgmt Omers Private Equity UK 835 1,511 1.8x 14.4x June Bio-Reference Laboratories Opko Health US 787 1,337 1.7x 12.6x June May Synlab (Majority stake) Labco Cinven DE 756 1,750 2.3x 12.1x Cinven FR 650 1,200 1.8x 9.1x AVERAGE 2.2x 11.5x 2014 November June Covance Zygo Corporation Labcorp AMETEK US 2,465 5,320 2.2x 16.5x US 1421 257 1.8x 13.0x February January Maxxam Analytical International Corporation Bureau Veritas SA Diagnósticos Da América Sa CA 179 433 2.4x 12.5x Cromossomo Participações li Sa BR 1,009 1,420 1.6x 8.7x AVERAGE 2.0x 12.7x * eurofins Source: Mergermarket, Company announcements, Bloomberg Terminal, Estimates based on publicly available information 43#44eurofins Eurofins' strategy aims at building long lasting competitive advantage in very attractive markets • Leading technology Competence Centres & R&D activities Quality of customer service • Proprietary technologies (e.g. proof of origin, virus syndromic panels, authenticity testing, etc.) • • • • Continuous development/acquisition of advanced technologies Best in class state of the art laboratories One stop shop International network operating across more than 50 countries Vast technological portfolio with more than 200,000 validated methods • Over 450 million tests performed per year • But one contact person for each customer at their local laboratory • Extensive expertise in local regulations for all major markets, and one-stop contact for compliance in multiple countries Globally reliable standards of high quality and consistency International key accounts management Internet-based transactions and access to testing results Pure-play laboratory operator Industrialised processes, bespoke IT solutions Unrivalled expertise accessible to all customers Continually expanding geographical coverage Proven operating model that can be rolled-out in various/multiple markets 44#45Credit Suisse report shows that family-owned businesses outperform their peers* Figure 4: Market-capitalization-weighted and sector-adjusted returns - family-owned alpha through time 300 250 200 150 100 50 0 Jan-06- Oct-06- Jul-07 Apr-08- -60-uer Family universe Oct-09- Jul-10 Apr-11 Jan-12 Oct-12 Jul-13 Apr-14 Jan-15 Oct-15 Non-family universe Jul-16- mm Apr-17 Jan-18 Oct-18 Jul-19- Apr-20 Family-owned companies outperform non-family-owned peers... eurofins ...supported by superior growth and Profitability Revenue and EBITDA growth is stronger, EBITDA margins are higher and cash flow returns are better. Family-owned companies also appear to have a greater focus on innovation as research and development (R&D) spending is higher. Family-owned companies have a longer-term and conservative focus Company interviews show: family-owned companies have above- average-quality characteristics than non-family owned peers. Family-owned companies on average tend to favor capital preservation and long-term value creation rather than more short-term gains. Family-owned companies on average tend to have slightly better results in terms of ESG scores than non-family-owned companies. Family-owned companies outperformed in every region (excess returns in Asia ex Japan broadly in line with those in Europe, given an annual average outperformance since 2006 of 500 basis points) and in every sector. *Source: Credit Suisse Research Institute: The Family 1000: Post the pandemic; September 2020 45#46Contents ■ Executive Summary ■ Market & Strategic Positioning Biopharma Testing Services Food Testing Environment Testing Clinical Diagnostics Other ■Financial review - ESG ■ Outlook ■ Summarised Financial Statements ■ Appendix eurofins 46 46#47The Pharma testing market is both healthy and full of potential Need for big pharma companies to expand new drugs pipelines Rapid technological change & increasing complexity in testing require ongoing investment in technology & expertise eurofins • • • The increasing complexity of clinical trials leads to increasing amounts of diagnostic procedures performed per patent Regulatory bodies (e.g. FDA) are demanding more study data to improve safety New wave of biologics require more testing Clinical trial processes are becoming increasingly rigorous to ensure drug efficacy The spend per drug trial is rapidly increasing Greater trial complexity & size will increase likelihood of using CROS 47#48• Underlying trends are intact for continued growth Worldwide Drug R&D Spending ($ bn) WW Pharma R&D Spend ($bn) eurofins 20 220 200 +16% 213 207 202 +14% 180 196 189 160 179 182 +12% 168 +3.0% CAGR 2018-24 160 140 +10% 150 145 120 137 136 138 129 +6.7% +8% +6.2% +4.2% CAGR 2010-18 +6.5% 100 +6% +4.4% 80 60 +5.1% +3.7% +4% R&D Spend Growth (%) • +4.0% The Drug Discovery market is growing rapidly thanks to increasing R&D budgets, applicability of big data and artificial intelligence and cost optimisation requirements. It is estimated to grow at a CAGR of 14% between 2020 and 2025 to reach USD 21.4bn by 2025* In 2020 the FDA approved 53 novel drugs and 27 in H1 2021** The FDA has approved 29 biosimilars*** since 2015 +3.5% +3.2% 40 +2.8% +2.7% +2% О +16% 20 +0% • -0.4% 0 -2% Drug approvals fuel reinvestment across the R&D value chain Record cash on biotech balance sheets provides R&D funding through 2020 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Source: EvaluatePharma, May, 2019 Sponsors outsource drug development to: - Reduce their fixed cost base - Access competencies that they do not have in-house - Access experience and regulatory expertise in new geographies • R&D outsourcing rising rapidly: - In 2018 drug sponsors spent ca.$86bn on outsourced R&D services surpassing spend on internal staff and infrastructure by ca. $20bn, suggesting over 56% of R&D services are now outsourced by drug sponsors - According to the Tufts Center for the Study of Drug Development, study initiation cycle time is 77 days faster for CROS identifying and managing new investigative sites, compared to studies managed directly by drug sponsors - R&D pipelines continue to grow and a growing number of smaller pharma/biotech companies are entering the market Source: Tufts Center for the Study of Drug Development (Tufts CSDD), 5 Mar, 2019 * https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html?gclid=EAlalQobChMlq9j7kaOA8glVpCs4Ch1jmQK8EAAYASAAEgJ9QfD_BWE Note: this study includes markets and sub segments not served by Eurofins ** https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021-*** https://www.fda.gov/drugs/biosimilars/biosimilar-product-information 48#49More than 90% of the top 20 largest global biopharma companies are clients of Eurofins * eurofins Eurofins biopharma locations Global CRO Market Outlook* Figure 1: The clinical CRO market will grow 7% (2015-2020E CAGR); outsourced penetration will go to 50% $35 60% $in bilions $31 $30 $29 55% $27 50% $25 50% $25 $24 $20 $19 $17 $18 $22 40% $22 45% 41% 40% $15 35% 34% 35% $10 $5 30% 25% $0 20% 2011 2012 2013 2014 2015 2016E 2017E 2018E 2019E 2020E Clinical CRO Market (loft axis) --Outsourced Penetration (right axis) Note: Clinical CRO market includes only Clinical, excludes Discovery, Preclinical, Central Laboratory, and Post-Approval/Commercialization *Source: CRO Industry Primer, 20 June 2016, Credit Suisse Eurofins' site map as of December 2020 Top 10 global biopharma companies** Johnson & Johnson (US) Roche (CH) Pfizer (US) Bayer (DEU) Novartis (CH) Merck (US) GlaxoSmithKline (UK) Sanofi (FR) AbbVie (US) Abbott (US) **Source: https://www.pharmapproach.com/top-10-pharmaceutical-companies-in-the-world/ 49#50Contents ■ Executive Summary ■ Market & Strategic Positioning Biopharma Testing Services Food Testing Environment Testing Clinical Diagnostics Other ■Financial review ■ ESG ■ Outlook ■ Summarised Financial Statements ■ Appendix eurofins 50 50#51The Food testing market enjoys robust growth drivers * eurofins Food scares and crises, widely covered in the media Globalisation: Raw materials sourced from countries with different QC practices Consumers' increasing awareness and demand for safe and high quality food Outsourcing of industry's internal or state-owned laboratories ☐ ☐ Compels industry to strengthen its testing programs New products (GMOs, new packaging, etc.) create need for new tests Governments increase regulations on food control Brands have become more global and vulnerable to contaminations Transparency and traceability are becoming the priorities Increasing pressure on producers and manufacturers to invest in testing Demand for a high quality, state-of-the-art, international network of laboratories 51 554#52Eurofins' Food & Feed testing offering is the most comprehensive in the market Agricultural production, product development * eurofins Production Retail & Distribution Microbiology Sensorial Dioxins Veterinary drug residues Vitamins Quality Control Authenticity Pesticides Organic residues POPS Labelling GMO Mycotoxins Allergens Heavy metals Irradiation Nutritional Purity 52 42#53High profile food scares have expensive consequences for producers... eurofins Brand / Year Contamination Impact Cost Country 2021 Tyson Foods Inc. Listeria contaminating ready-to-eat chicken products Recall of some 8,955,296 pounds of ready-to-eat chicken products due to a potential contamination with Listeria monocytogenes Unquantified Over 1,000 items recalled across European retailers/supermarkets Unquantified Source The New York Times 2019 Wilke Waldecker 2018 Fleisch- und Wurstwaren USA JBS Tolleson Listeria outbreak contaminating meat products Listeria and salmonella in ready-to- eat salads and premade food items Fipronil in European eggs 5 deaths after contracting listeria infections About 6.5 million pounds of beef was recalled by Arizona-based meat producer JBS Tolleson. Millions of pounds of ready-to-eat salads and premade food items at several big name retailers such as Harris Teeter, Kroger, Whole Foods, 7-Eleven, Trader Joe's and Walmart have been recalled due to the potential risk of listeria and salmonella contamination. Farms shut down in the Netherlands, Belgium, Germany and France. Supermarkets have also withdrawn millions of eggs from sale 2017 Europe 2015 USA Chipotle E. coli outbreak at restaurants in multiple states 53 people sick, 22 hospitalized in 9 states across the U.S. 15% decline in like-for-like sales during the period Unquantified Unquantified - USD 8bn Food Safety News / The Brussels Times USA Today BBC news CNN 2013 Europe Beef products contaminated with horse meat Sales of frozen burgers plunged 43% and frozen ready meals fell 13% in the UK between 21 Jan - 17 Feb, 2013, at the height of the scandal Market value lost - €360m The Guardian Dioxins in eggs, poultry and pork About 3,000 tons of feed contaminated with oil intended for use in bio-fuels, 4700 farms closed, revenues lost, tightening regulation 70 people sick, 25 people hospitalized, job losses, withdrawal of 86 million "cookies-worth", court proceedings initiated 2011 Germany 2009 Nestlé E. coli in cookie dough 2008 Kellogg's, Salmonella in peanut butter 9 dead, 683 people sick, global recall of peanut butter and related products (1,600 types of products involved) Unilever, General Mills 2008 Irish pork Dioxins Recall of Irish pork products, job losses, destruction of 100,000 pigs 2008 Sanlu/ Fronterra Melamine in dairy products 50,000 infants ill, 6 deaths, global recall of dairy and related products, criminal charges in China + global brands Market value lost for Tesco Unquantified Unquantified USD 100m Est. only for Kellogg's > €300m Unquantified BBC News CNN Health Bloomberg Irish Exporters Association BBC News 53#54* eurofins Eurofins is meeting the demands of global players for high quality testing The largest global food & beverage producers and retailers are clients of Eurofins Food and Beverage Nestlé PepsiCo Switzerland USA Unilever UK /Netherlands Mars USA Coca-Cola USA Danone France Kraft Heinz USA McDonalds USA Kelloggs USA Eurofins' site map as of December 2020 Pernod Ricard France Retailers Wal-Mart Stores USA CostCo USA Kroger USA Kid Germany Ardi Carrefour Tesco ITM Enterprises Metro AG Casino Guichard Germany France UK France Germany France 54#55Contents ■ Executive Summary ■ Market & Strategic Positioning Biopharma Testing Services Food Testing Environment Testing Clinical Diagnostics Other ■Financial review ■ ESG ■ Outlook ■ Summarised Financial Statements ■ Appendix eurofins 55 55#56The Environmental testing market continues to grow * eurofins Rise in contamination & pollution issues Progress in epidemiology & medicine has identified more compounds as toxic Increasing demand by citizens for a clean environment ■ EU expanding regulation (e.g. REACH) Increasingly long list of products identified as toxic ■ Requirement for more sophisticated analyses and more expensive equipment ■ Increasing demand for per- and polyfluoroalkyl substances (PFAS) testing Compels industry to increase testing and outsource internal labs 56 56#57• Eurofins serves all the main environmental testing markets Eurofins is the No.1 environmental testing service provider in the world* eurofins THE 口 Lancaster Environmental Testing is the laboratory of choice for Fortune 500 companies in the USA WATER Eurofins' site map as of December 2020 Drinking water and groundwater analysis Full range of contaminants AIR • Outdoor pollutants • Indoor and ambient pollutants *Management estimate based on available information • Consulting and sampling companies are natural partners SOIL Analysis of soil for full range of contaminants 44 57#58Contents ■ Executive Summary ■ Market & Strategic Positioning Biopharma Testing Services Food Testing Environment Testing Clinical Diagnostics Other ■Financial review ■ ESG ■ Outlook ■ Summarised Financial Statements ■ Appendix eurofins 58#59Eurofins is setting up a global network of clinical genetics laboratories * eurofins Nowadays, Clinical Genetics is a central element in healthcare and Clinical Diagnostics, contributing to every stage of patient care Throughout all three of Eurofins' start-up programs, several large investments in global clinical genetics laboratories have been made, giving Eurofins a unique portfolio of services for cutting-edge applications. • Eurofins, through acquisitions and start-up laboratories, is investing heavily in advanced technologies: EGL Predictive tests for genetic diseases and oncology Side effects/efficacy of drugs • Rare diseases testing Non Invasive Prenatal Testing Personalized medicine offering patients individualized treatment based on their genetic and metabolic profiles Next Generation Sequencing -Whole Genome Sequencing NTD USA Boston Heart Europe Developments in genetics and genomics will have a significant impact on tomorrow's clinical diagnostics market APAC Vira Cor Diatherix Biomnis Megalab Lifecodexx Genoma Clinical Genetics Bangalore start-up Clinical Genetics Tokyo start-up Since 2014, Eurofins has already developed a network of laboratories focused on clinical genetics in several countries around the globe, including: India, Japan, France, Germany, Spain, Italy and the USA 59#60Eurofins is expanding its global offering in non-invasive prenatal testing (NIPT) MAGENOMA® Molecular Genetics Laboratories Group * eurofins life codexx In September 2017, Eurofins' Genoma introduced GeneSafe™, the first non-invasive prenatal test that screens for both de novo (non-inherited gene mutations) and inherited single-gene disorders. " GeneSafe™ detects over 40 severe genetic disorders: that may occur in absence of any family history of the condition. GeneSafe™ is the first NIPT to detect disorders that are increasingly prevalent with advanced paternal age: later-stage parenthood is becoming increasingly common. GeneSafe TM is more advanced than other NIPTs currently available: identifying fetal conditions that could be missed by traditional prenatal testing. Many disorders screened with GeneSafe™: GeneSafe Are not typically associated with abnormal prenatal ultrasound findings. " May not be evident until late second/third trimester or even after delivery. In July 2017, Eurofins acquired a majority stake in LifeCodexx AG, Europe's first NIPT provider and one of the most innovative NIPT players. LifeCodexx has been developing innovative and clinically validated tests since 2010. LifeCodexx's PrenaTestⓇ was Europe's first NIPT: for the determination of the most common chromosomal disorders in unborn children. This was a substantial development that changed prenatal diagnostics considerably. LifeCodexx, following a positive CE marking, began rolling-out their unique qPCR-based NIPT capabilities in December 2016: leading to increased cost- efficiency and rapid turnaround time, another significant innovative step in the NIPT field. Eurofins NIPTs are very reliable (>99% of conclusive results), fast (turnaround time under 2 weeks, qPCR assays only take 2-3 days) and simple (only a small blood sample required). Eurofins is the first provider to offer the aforementioned novel NIPT tests, GeneSafe TM and qPCR-based NIPT, to the market. 60#61• Eurofins Specialized Clinical Diagnostic Network Evolution Establishing platform to deploy genomics expertise for development of innovative clinical diagnostic tests to serve global healthcare community One of the world's leaders in Genomics Services Custom DNA Sequencing & Synthesis Gene Synthesis/Molecular Biology Genotyping & Gene Expression Next Generation Sequencing 2000-2009 Genomics Services ViraCor LABORATORIES •Reference lab for transplantation & time-sensitive tests •High-complexity testing for infectious diseases, allergy and immune disorders Eurofins commences genomics footprint with the acquisition of Medigenomix (2001), MWG (2004), Operon (2007) and AROS AB (2013) Application of Genomics Technology in Bioanalytical testing Eurofins deploys genomics technology to further develop its analytical portfolio for food, environment and pharmaceutical testing 2010-2014 bostonheart diagnostics EMORY GENETICS LABORATORY • First academic lab to bring Next Generation Sequencing (NGS) to commercial market Renowned for testing rare genetic disorders •Carrier screening, cancer testing and exome sequencing Leading diagnostics lab for cardiovascular disease Proprietary plus clinical and genetic tests & cardio- informatics capabilities DIATHERIX •Proprietary technology (TEMP- PCR) for single-tube identification of multiple pathogens • Ultra-fast and precise, highly parallel detection of infectious diseases and drug resistance biomnis NTD Labs •Reference lab for reproductive genetic testing Pioneer in first trimester non- invasive prenatal screening test for Down Syndrome 2015 • One of the largest esoteric diagnostic labs in Europe •Strong reputation in infectious diseases & clinical trials for the pharma industry bio-access * eurofins Genomics is one of the key technologies enabling personalised medicine Hy LABOR AM HIGIENCINSTITU •Largest clinical diagnostics provider in North Rhine- Westphalia Access to over 900 physicians, 120 hospitals and around 20 local health authorities MEGALAB •One of the top 5 clinical diagnostic laboratory groups in Spain Largest national coverage VIAVRL Laboratories • One of the leading groups of Reference lab focused on medical biology labs in donor eligibility and France microbiology testing for transplantations. •Competency in immunology, oncology and infectious diseases • Broad menu of infectious disease screening assays KLINISCH LABO VAN POUCKE • A leading Belgian laboratory performing human medical testing covering all branches of clinical biology 2016-2020 MAGENOMA® Molecular Genetics Laboratori Group NMDL LCPL Specialisten in Medische Diagnostiek •Provides molecular diagnostics and pathology lab services • Serves over 2,000 General Practitioners in the NL One of the leading specialty diagnostics testing providers in Italy Strong reputation in molecular biology and cytogenetics life codexx • European specialist in non- invasive prenatal testing (NIPT) •Launched PrenatestⓇ in 2012, the first NIPT in Europe PASTEUR MEDICINA ARSTIRA Comp.com: Énotícia. ⚫leading player in clinical diagnostics in greater area of Santos, Sao Paulo state • LABS • Provides laboratory services specialized for transplantation and biomedical applications. TRANSPLANT GENOMICS™ Start-up with innovative test (TruGrafⓇ able to rule out silent subclinical rejection in kidney transplant recipients with stable renal function GeneTech Inc. •The pioneer in non-invasive prenatal testing (NIPT) and a leading player in genetic analysis in Japan 61#62* eurofins Eurofins Specialised Clinical Diagnostic Footprint Establishing leadership in targeted higher-growth niche areas of the clinical testing market * VRL bostonheart diagnostics Viracor Eurofins Clinical Diagnostics Eurofins Pre-Transplant Testing Diatherix Eurofins Clinical Diagnostics eurofins eurofins Labo Van Poucke Transplant Genomics eurofins NMDL-LCPL * eurofins MML Alrijne eurofins Salux до eurofins Biomnis eurofins Pathology eurofins Biologie Médicale eurofins Clinicas Pinto de Barros eurofins EGL Genetics eurofins MEGALAB NTD Eurofins Clinical Diagnostics eurofins Biologie Médicale Centro de Genomas Eurofins கு PASTEUR MEDICIDA ELAGRESTIC Comprimatimente com Exotinia GENOMA Molecular Genetics Laboratories Group Clinical Diagnostics eurofins GeLaMed Humangenetik Dr. Finckh Dortmund Praenatal-Medizin Muenchen eurofins -GeneTech LifeCodexx eurofins Biomnis Middle East LLC eurofins Clinical Genetics Japan eurofins Clinical Genetics India eurofins Clinical Diagnostics Pte Ltd 62 29#63Eurofins has built a valuable portfolio of Routine and Specialized Clinical Diagnostics Laboratories in France * eurofins Eurofins Clinical Diagnostics operations in France amount to ca. €400m of revenues. These €400m revenues were acquired over the last 4 years for ca. €600-700m, representing an average EV / revenue acquisition multiple of 1.5x to 1.75x. Over the last three years, Clinical Diagnostics companies in France have, on average, been acquired at over 3x target revenues. Comparable M&A transactions in Clinical Diagnostics in France: Date Target Acquirer EV in €m EV / target revenues March 2018 BIO7 Cerba 500 4.5x January 2017 Cerba PSP, Partners Group 1,800 2.9x 63 63#64Contents ■ Executive Summary ■ Market & Strategic Positioning Biopharma Testing Services Food Testing Environment Testing Clinical Diagnostics Other ■Financial review ■ ESG ■ Outlook ■ Summarised Financial Statements ■ Appendix 449 64 eurofins#65Eurofins has also established global leadership positions in 5 high potential niche markets eurofins Genomic Services Agroscience CRO** Services Discovery Pharmacology Cosmetics Testing Eurofins position N°2* Worldwide N°1* In Europe Start 2004 N°1* worldwide Start 2006 N°1* worldwide Start 2010 N°1* worldwide Start 2014 Advanced Materials Sciences N°1* worldwide Start 2017 Business line description Global network of state-of-the- art laboratories offering the most advanced technologies for genetic analysis of all kinds of samples and fast DNA-synthesis service. Provides opportunities to replace traditional analytical methods by genomics methods that offer process improvements and economies of scale (e.g. Pathogen testing in food and environment) Eurofins Agroscience CRO Services has the broadest global footprint of all CROS, offering a unique portfolio of expertise including analytical, regulatory and field support to plant breeders, agrochemical, biopesticide, biocide and fine chemical manufacturers. Eurofins Pharma Discovery Services is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. Eurofins also offers a broad portfolio of over 3,500 drug discovery services and 1,800 products. Listed or larger peers IDT/Danaher, Genewiz/Brooks, etc. SGS *To the best of Eurofins' knowledge, based on data available to the Group Evotec, Albany Molecular Research, Charles River, etc. **CRO: Contract Research Organization Network of laboratories offering raw a full range of services to retailers and cosmetic manufacturers from materials suppliers to finished products producers. Services include: consulting, physico- chemical analysis, microbiology, in-vitro studies, clinical studies and consumer research. Eurofins EAG laboratories is a scientific leader helping clients understand the physical structure, chemical properties and composition of their materials. EAG offers the most comprehensive portfolio of analytical techniques including: advanced microscopy, chemical analysis, compositional analysis, metallurgical analysis, identification, contaminant deformulation, trace elemental analysis, etc. Exponent, Element Materials, SGS etc. 65 559#66• • • • • • Eurofins is developing high Barriers to Entry around its businesses Offering a premium quality service ... Portfolio: over 200,000 analytical methods - unique in the world and ahead of competition Global laboratory network: fully set up for cross-selling worldwide to customers Accreditations: multiple international accreditations One-stop shop: single point of contact for compliance to regulations of many countries Standardised testing in more than 50 countries Sales and marketing: international teams plus dedicated key account management Reputation: high standards of quality and consistency - the Eurofins brand Internet: web-based transactions and online access to testing results increase switching costs • * eurofins and leveraging internal efficiencies Industrialising the laboratory process: rationalisation of sites and personnel Competence Centres: high volume laboratories providing highest levels of expertise and service • Technology: the latest available in the market providing the most accurate results . Economies of scale in Group purchasing and sales functions • IT systems: cross-Group information tools and standardised production systems 66 60#67Contents ■ Executive Summary ■ Market & Strategic Positioning ■Financial review ■ ESG ■ Outlook Summarised Financial Statements ■ Appendix 67 49 eurofins#68Record H1 results Half Year 2021 Adjusted¹ SDIS2 Results Half Year 2020 +/- A Reported Results Adjusted¹ SDIS 2 Results Reported Results Adjusted Results * eurofins +/- A Reported Results Key Highlights • Record first six months, with strong growth of revenues (EUR 3,272m, +41% vs H1 2020) thanks to strong growth of Core Business and sustained revenues from COVID testing & reagents (close to EUR 750m) Record adjusted EBITDA of EUR 1,008m (+104% year-on-year) and 30.8% margin (vs 21.2% in H1 2020) Reported Net Profit5 of EUR 415m (12.7% of revenues, +339% vs EUR 95m in H1 2020) Record EPS of EUR 2.17 (EUR 3.05 adjusted), up 317% vs H1 2020 Revenues, EURM 3,272 3,272 2,323 2,323 +41% +41% EBITDA³, EURM 1,008 -19 989 493 -35 459 +104% +116% EBITDA Margin, % 30.8 30.2 21.2 19.7 +960bps +1,050bps EBITAS4, EURM 813 -29 785 311 -52 259 +162% +203% Net Profit 5, EURM 582 -167 415 187 -92 95 +211% +339% Basic EPS6, EUR 3.05 -0.87 2.17 1.03 -0.51 0.52 +196% +317% 1 Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding "Separately Disclosed Items" 2 Separately disclosed items - include one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions, net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income) and the related tax effects 3 EBITDA - Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions 4 EBITAS - EBITDA (as defined above) less depreciation and amortisation 5 Net Profit - Net profit for equity holders after non-controlling interests but before payment to Hybrid capital holders 6 Basic EPS - Basic EPS attributable to equity holders of the Company and hybrid capital investors 68 80#69Very strong results in terms of revenues and margin, ahead of the Group's most recent objectives Full Year 2020 Full Year 2019 Adjusted¹ SDIS 2 Results Reported Results Adjusted¹ SDIS 2 Reported Results Results +/- A Adjusted Results +/- A Reported Results Revenues, EURM 5,438.8 5,438.8 4,562.8 4,562.8 +19.2% +19.2% EBITDA³, EURM 1,412.7 -61.8 1,350.8 930.7 -97.8 833.0 +51.8% +62.2% EBITDA Margin 26.0% 24.8% 20.4% +18.3% 560bps +650bps (%) EBITAS4, EURM 1,023.6 -98.7 924.9 573.5 -136.5 437.0 +78.5% +111.6% Net Profit to 706.5 -167.0 539.4 359.4 -164.1 195.2 +96.6% +176.3% Equity, EURm Basic EPS5, EUR 3.63 -0.91 2.71 1.75 -0.93 0.82 +107.4% +230.5% eurofins Key Highlights Very strong revenue growth in FY 2020 translated into improved margin, with adjusted EBITDA margin up by 560bps year-on- year Adjusted EBITDA of EUR 1,413m, significantly above the Group's latest EUR 1,300m adjusted EBITDA objective for FY 2020 set in December 2020 EPS5 increased by 107% to EUR 3.63 in FY 2020, largely driven by the increase in profitability and lower tax paid vs FY 2019 thanks to the usage of loss-carry forwards 1 Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding "Separately Disclosed Items". 2 Separately disclosed items - include one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions, net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income) and the related tax effects. 3 EBITDA - Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions. 4 EBITAS - EBITDA (as defined above) less depreciation and amortization 5 Basic EPS attributable to equity holders of the Company 69#70Controlled Net Working Capital use 6.4% Net working capital as a % of revenues 5.3% 282 250 6.6% 440 * eurofins Key Highlights Net working capital back to 2019 mid-year levels, at 6.6% of revenues, as temporary postponements of social charges and tax payments put in place by some governments in 2020 reversed in 2021 • DSOs¹ and DPOS² stable at 58 days and 52 days respectively Stable inventory at 2.5% of revenues, largely related to the ramp-up in response to COVID-19 H1 2019 H1 2020 Net working capital (NWC) Єm H1 2021 NWC/Revenues (Last Q*4) 1 DSOS: Days of Sales Outstanding: Trade account receivables excluding VAT, accrued sales, WIP, less Advanced payments and Deferred revenues by external sales of last three months multiplied by 90 days 2 DPOs: Days of Payables Outstanding: Trade account payables excluding VAT less prepaid expenses and deferred charges by purchases and Capex of last three months multiplied by 90 days 70 70#71Net working capital intensity improved in FY 2020 NWC intensity 5.3% 5.3% 262 250 308 4.5% FY 2019 H1 2020 FY 2020 Net working capital (NWC) Em NWC/Revenues (Last Q*4) *Accounts receivable including contract assets Accounts receivable* Inventory Accounts payable 1.6% 2.6% 2.3% 157 124 79 FY 2019 H1 2020 FY 2020 20.4% 20.2% 1,194 1,001 957 17.5% FY 2019 * eurofins 8.0% 542 Key Highlights Net working capital intensity decreased by 80bps in FY20 to 4.5% of revenues. The absolute change in NWC was largely driven by the impact of COVID-19 related activities Significant improvement in Days Sales outstanding (52 vs 60 days) balanced by slightly degraded Days Payables outstanding (53 vs 55 days) Inventories doubled during 2020 to EUR 157m to enable the Group to respond quickly to COVID-19 testing and reagents demands H1 2020 FY 2020 8.3% 410 389 8.2% FY 2019 H1 2020 FY 2020 71#72Consistent capital investments to develop a unique network of laboratories and state-of-the-art IT solutions * eurofins Net Capex (EUR m) Infrastructure1 Capex (EUR m) IT 2 Capex (EUR m) ■Machinery and Laboratory Equipment ■Real Estate 361 319 350 2018 2019 2020 270 274 240 2018 2019 2020 64 64 19 64 FY 2020 Key Highlights Net Capex/Revenues ratio fell to 6.4% of Group's revenues in FY20 vs. 7.0% in FY 2019 as the Group entered the final stage of its significant 2015-2020 investment programme Net Capex spend of EUR 350m, with Buildings and Leasehold improvements representing ca. 40%, Laboratory equipment ca. 35%, and IT Capex ca. 20% Net Capex spend slightly above the Group's most recent objective of EUR 300m, reflecting the requirements to ramp up the Group's COVID-19 testing capacity 2018 2019 2020 1 Infrastructure spend includes Land, Building and Leasehold Improvements, Assets in Progress and Machinery and Laboratory Equipment (net of proceeds from sales) 2 IT intangible assets (e.g. software) and hardware capex 72 12#73Return on Capital Employed * eurofins Before IFRS 16 implementation After IFRS 16 implementation2 - ■ Heavy investment phase during 2016-2020 for: ■ Laboratory extensions of existing sites many new sites in 2019 and 2020 not yet highly utilised ■ Start-up laboratories resulting in early operating losses (part of SDI's) included in capital employed but not contributing profits infrastructure set up, development and deployment of new generation IT solutions not yet generating positive impact on efficiency and margins (EURM) 2016 2017 2018 2019 2020 Average capital employed at the end of 2,399 2,803 4,521 6,304 6,423 each quarter Average capital employed excluding Goodwill at the end of each quarter 657 785 1,080 1,925 1,996 ■ IT Adjusted EBITAS 358 400 521 574 1,024 ROCE¹ 9.1% 15.9% ROCE (return on capital employed 54.4% 50.9% 48.2% 29.8% 51.3% ☐ excluding Goodwill) ■ Resulting in dilution of ROCE short-term ROCE = adjusted EBITAS/ average capital employed over previous 4 quarters 2 IFRS 16 added c. EUR 490m right-of-use (ROU) assets in 2019 and c. EUR 514m in 2020 into the capital employed figures ■Goodwill from M&A with over 110 acquisitions in 2017 and 2018 increasing capital base Restructuring of acquired laboratory network (part of SDI's) to fit with hub-and-spoke model ■ Hurdle rate of 12% ROCE (pre-tax) by Year 3 ■ROCE should start increasing again when investment phase is completed and Eurofins is reaping the benefits from past investments 73#74Very solid liquidity position and significant reduction in leverage Leverage1 Debt maturity profile (EUR m) 800 Hybrid (1st call) ■Schuldschein * eurofins 3.4x 3.2x 2.5x Ili 1.6x 700 600 500 400 300 T 400 750 1.0x 447.75 200 300 300 302.25 233.5 100 0 FY2018 FY2019 H1 2020 FY 2020 H1 2021 45.5 175.5 127.5 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1 Leverage: net debt/ PF12M adjusted EBITDA (corrected for the estimated impact of the cyber-attack in 2019) Key Highlights Reduction of close to EUR 500m in corporate senior gross debt following successful refinancing exercises Capital management, driving 10% reduction in net debt, from EUR 2,242m at December 2020 to EUR 2,015m at the end of June 2021 Leverage ratio significantly decreased to 1.0x at the end of June 2021, from 1.6x at the end of December 2020 and 2.5x at the end of June 2020 Refinancing exercises carried out in H1 2021 enabled the Group to secure a €750m Eurobond issued in May 2021 with a 10-year maturity at an annual interest of 0.875% and will bring the average cost of financing to below 1.8% from H2 2021 onwards Investment grade credit rating of BBB- with stable outlook assigned by Fitch Ratings in May 2021 in addition to Moody's similar long-term issuer rating of Baa3 with stable outlook assigned in July 2020 Overall, at June-end 2021, Eurofins enjoys a strong liquidity position and a longer debt maturity profile 74#75Solid Balance Sheet * eurofins Hybrid - Ba2 rated • €300m hybrid issued in September 2019, callable at par by Eurofins in August 2022. Bears a fixed coupon of 2.875% until first call, Euribor 3m + 605.8 bp thereafter if not called • €300m hybrid issued in April 2015, callable at par by Eurofins in April 2023. Bears a fixed coupon of 4.875% until first call, Euribor 3m+ 701 bp thereafter if not called • . €400m hybrid issued in November 2017, callable at par by Eurofins in November 2025. Bears a fixed coupon of 3.25% until first call, then 2.667% until Second Step-Up Date and 3.667% thereafter if not called. • On these hybrid instruments outstanding in 2021, a first distribution on hybrid capital of EUR 14.6m was paid in April (EUR 300m at 4.875%) Eurobond - Baa3/ rated • €650m Eurobond issued in Jul 2017 with a nominal amount outstanding of €447.7m, 7-yr maturity (Jul 2024) at an annual interest of 2.125% • • €600m Eurobond issued in May 2020 with a nominal amount outstanding of €302.2m, 6-yr maturity (Jul 2026) at an annual interest of 3.75% €750m Eurobond issued in May 2021, 10-yr maturity (May 2031) at an annual interest of 0.875% Schuldschein €550m Schuldschein loan issued in Jul 2018 with a nominal amount outstanding of €232m offering a blended interest rate of 1.38% with an average maturity of 5 years. Schuldschein was structured with maturities of 4-yr (Jul 2022) and 7-yr (Jul 2025) with both fixed and floating interest rates. Floating tranches have been repaid in 2020 and in January 2021. • €350 Schuldschein loan issued in Oct 2020 offering a blended interest rate of 1.78% with an average maturity of 7.8 years. This Schuldschein loan is structured in tranches of 5, 7 and 10 years, with both fixed and floating interest rates, with more than 85% of the transaction on the 7 and 10-year tenors. *Calculated on the fixed tranches 75#76Audit Coverage Continued Expansion * eurofins In 2019, the AGM appointed Deloitte Audit as auditor resulting in improved audit coverage by Tier 1 and Tier 2 auditors. For the year ended 31 December 2020, the coverage of Deloitte Audit and other auditors was as follows: 2020 accounts 2019 accounts coverage for Tier 1 & Tier 2 Consolidated Financial auditors' coverage Statements1 External Sales 71% Audit coverage for Tier 1 & Tier Consolidated auditors' coverage Financial Statements for statutory audits² 94% 2 Audit EBITDA Total assets 80% 83% 98% 97% (1) Including review by Deloitte Audit of component auditors works (2) Tier 1 (PwC, Deloitte, EY, KPMG) Tier 2 (RSM, Grant Thornton, BDO, Mazars, Moore Stephens, Crowe, Baker Tilly) for statutory audits² 70% 84% 92% 99% 85% 97% 76#77Contents ■ Executive Summary ■ Market & Strategic Positioning ■ Financial review - ESG ■ Outlook ■ Summarised Financial Statements Appendix eurofins 77#78Eurofins is positively contributing to 16 of 17 United Nations Sustainable Development Goals (UNSDGs) * eurofins We are aligned with 16 out of 17 UNSDGs both at central level, through the Eurofins Foundation and through the activities of our business lines |1 NO POVERTY 2 ZERO HUNGER 3 GOOD HEALTH AND WELL-BEING 4 QUALITY EDUCATION 5 GENDER EQUALITY 6 CLEAN WATER AND SANITATION 7 AFFORDABLE AND CLEAN ENERGY 8 DECENT WORK AND ECONOMIC GROWTH SSS 9 INDUSTRY INTROVATION INDUSTRY, INNOVATION 10 REDUCED INEQUALITIES 11 SUSTAINABLE CITIES AND COMMUNITIES 12 RESPONSIBLE CONSUMPTION AND PRODUCTION 13 CLIMATE ACTION 14 QO LIFE BELOW WATER 15 ON LAND LIFE 16 PEACE, JUSTICE AND STRONG INSTITUTIONS SUSTAINABLE GOALS DEVELOPMENT 78#79Our Businesses are ESG positive • · * eurofins We help improve health outcomes, ensure food safety and protect the environment E.g., our Environment, Food and Feed Laboratories: Assess safety of the whole water cycle and analyse waste toxicity Monitor air pollution and soil quality Contribute to developing more sustainable agricultural practices/outputs Help minimise levels of pesticides, persistent organic/ chemical pollutants Provide audits to certify compliance with food safety and environmental standards Certify food packaging and contact materials, including their recyclability We have limited exposure to the carbon intensive industries such as oil and gas, fracking or transportation • <3 79#80We are an ESG enabler for our clients * eurofins • We help our clients improve their ESG measurement and monitoring • Our world-leading, multidisciplinary expertise in laboratory testing and monitoring directly promotes human safety and environmental protection, including: o Food Quality and Integrity o Environmental Safety Seed Development and Crop Production including alternatives to meat 。 Drug Development o Patient Care, from Prevention to Prognosis & Treatment o Hospitals, Industrial Sites and Offices Hygiene 80 80#81Our ESG roadmap 1. Embed ESG targets into leadership performance and remuneration from 2021 Carbon neutrality by 2025: 2. a. Launch a carbon footprint reduction programme at regional level, managed by our Business Leaders Establish a CO2 inventory (scope 1, 2, 3) by 2022 b. C. Set 2022-2023 CO2-quantified emissions reduction targets & associated implementable action plan at regional level 3. 4. 5. 6. Set up a Group-wide Sustainability Programme with consolidated methods, models and data Improve diversity, including % of women in leadership roles through our global Equality Driving Excellence (EDE) initiative Continue to increase the Eurofins Foundation's impact. In 2020, the Eurofins Foundation trebled its donation budget and is now directly supporting: a. Nearly 2x as many non-profit organisations worldwide compared to 2019 b. 75+ projects globally Board development with the appointment of two new independent directors*, to bring the total number to eight and achieve gender parity at Board level *Including to replace one retiring member eurofins 81#82Sustainability remains at the heart of Eurofins' activities eurofins In H1 2021 the Group continued to embed best practices and make further progress on all three dimensions of ESG: Established Sustainability and Corporate Governance Committee at Board level to demonstrate focus and commitment on these important topics Official roll-out of Eurofins' Carbon Footprint Reduction programme at regional level, with management responsibilities extended to local CO2 Champions and Business Leaders О Further progress made on Group-wide Carbon measurements, with aim to establish CO2 inventory1 by end of 2022 Formal adoption of ESG targets focused on gender diversity, safety, environment and compliance for all Business Units and more Senior leaders Significant ESG-related engagement efforts made at Group level, including increased interaction with leading rating agencies as part of our Group-wide Sustainability Programme: Eurofins' ESG rating by Sustainalytics improved from 'Medium Risk' to 'Low Risk' in June 2021 Corporate Governance: Formal appointment of two highly experienced independent directors who officially joined the Board on 22 April 2021, bringing the total number of members to eight, of which four are women Appointment of Lead Independent Director (Pascal Rakovsky) on 22 April 2021 1 Covering Scope 1, 2 and 3 82 82#83Global Equality Driving Excellence Initiative (EDE): 2020 Achievements and 2021 Goals 2020 achievements Increased Female Leadership Jan-20 Jan-21 Senior Leaders¹ 29 38 Male 26 31 Female 3 7 % Male 90% 82% % Female 10% 18% Global Equality Ambassador Council (33 members) eurofins 2021 goals Equality Targets in Leadership Performance encouraging YOY improvements Expanded Regional EDE Council Meetings EHEA Timely t AMERICAS Specific Measurable Achievable Realistic SMART G OALS ASIA PACIFIC Diversity Action Expanded to Stance against Racism and Support LGBTQ Rights "One of the best aspects of working at Eurofins is the acceptance my fiancé and I encounter on a daily basis with my co- workers and management. The normalisation of same sex relationships is a breath of fresh air that I never encountered at any previous workplace." Intranet, Newsletter & Employee NPS Survey eurofins curofins Mentoring Pilot paralleling software and internal process mmentorcliQ Internal Job Postings Visibility and Talent Pools S SmartRecruiters Brandon eurofins NPS 1 Senior Leaders groups represented the top 29 people in 2020 vs the top 38 in 2021 and are composed of all Regional Business Leaders and above 83 83#84Contents ■ Executive Summary ■ Market & Strategic Positioning ■ Financial review ■ ESG ■ Outlook ■ Summarised Financial Statements Appendix eurofins 84#852020 was another year of significant progress Reported Revenues, EUR m 7,000 * eurofins 6,237 6,138 6,000 SGS 5,905 5,422 5,471 5,566 5,188 5,312 5,439 5,100 5,000 4,635 4,689 4,796 5,235 BUREAU 4,549 VERITAS 4,172 4,601 3,902 3,933 4,563 4,000 3,781 3,375 3,129 3,165 3,000 intertek 2,901 3,084 2,468 2,321 2,365 2,448 2,971 2,537 2,000 1,410 1,226 1,950 1,044 1,000 2012 eurofins 2013 2014 2015 2016 2017 2018 2019 2020 Source: Companies Annual Reports. Reported revenue figures for Intertek and SGS translated into EUR using annual average exchange rates 85#86Outlook: 2021 objectives upgraded. 2022 and 2023 objectives excluding Covid unchanged for now eurofins We upgrade 2021 objectives by 13% for revenues and by 36% for EBITDA (all at average H1 2021 exchange rates). FY 2022 and FY 2023 remain unchanged at this time as the duration and magnitude of the COVID-19 related contribution remain impossible to quantify due to uncertainty on new variants and public policy responses. However it is likely that significant levels of testing for COVID-19 may unfortunately continue at a meaningful level at least in 2022. FY 2021 upgraded objectives ○ Revenues o Adjusted EBITDA EUR m 6,150 1,700 FY 2021 previous objectives1 EUR m Revenues 5,450 1,250 FCF-Firm 700 350 Adjusted EBITDA Net Capex SDI (at EBITDA le vel) M&A FY 20222 (Core Business excl. Covid and M&A beyond 31/12/2020) 30 150 о Revenues o Adjusted EBITDA O FCF-Firm 5,450 1,300 750 FY 20232 (Core Business excl. Covid and M&A beyond 31/12/2020) о Revenues o Adjusted EBITDA O FCF-Firm 1 Set on March 1, 2021 5,725 1,375 800 For 2022 & 2023, in addition to these organic objectives, potential proforma revenues from acquisitions of EUR 150m in 2021 and EUR 200m in both 2022 and 2023 (consolidated at mid-year), which would bring Group revenue objectives to: • EUR 5,700m in 2022 9 EUR 6,175m in 2023 2 2022 & 2023 objectives set at average 2020 exchange rates and excluding any revenues from COVID-19 testing and reagents and any M&A beyond 31/12/2020 (i.e. organic Core Business ex. COVID-19 objectives), assuming full return to normal of economies / markets to pre-pandemic levels 86#87Conclusion: our sustainable competitive advantage eurofins Best in class technology and quality give best brand protection N° 1 or 2 worldwide in most business lines Operating in more than 50 countries State-of-the-art laboratory infrastructure High switching costs for clients Good cash flow visibility Experienced multi-national leadership High-growth, non-cyclical markets driven by secular mega- trends Advancing globalisation but with very few global testing suppliers Fragmented competition & opportunities for consolidation Very recurring business; 5% - 12% typical historic organic growth for the last 20 years High barriers to entry • Track record of profitable growth - Strong ROCE and cash flow generation potential • . • ROCE* of 15.9% and ROE** of 26.7% in 2020 despite significant future-orientated investments and one-off restructuring costs. ROCE* excluding goodwill of 51.3% 5-year CAGR (FY 2015 - FY 2020): Revenues 23%, Net Operating Cash Flow 33% Large potential to roll out business model in fast growing economies Following past intense investment cycles Eurofins' network of laboratories is well positioned for the Group to achieve its objectives whilst gaining and maintaining leadership in multiple markets and improving profitability *ROCE = Adjusted EBITAS/Average Capital Employed over previous 4 quarters **ROE = Net Profit/Equity (excl. Hybrid) at the beginning of the year 87#88Contents ■ Executive Summary ■ Market & Strategic Positioning Financial review - ESG ■ Outlook ■ Summarised Financial Statements ▪ Appendix eurofins 88#89Summarised Income Statement For the six months ended 30 June * eurofins 2021 2020 In millions of EUR Revenues Adjusted results Separately disclosed items Reported results Adjusted results Separately disclosed Reported results items 3,272.3 3,272.3 2,323.4 2,323.4 Operating costs, net -2,264.2 -19.0 -2,283.2 -1,830.0 -34.9 -1,864.8 EBITDA 1,008.1 -19.0 989.1 493.5 -34.9 458.6 Depreciation and amortisation -194.8 -9.6 -204.4 -182.7 -17.0 -199.7 EBITAS 813.3 -28.5 784.7 310.7 -51.9 258.9 Share-based payment charge and acquisition-related expenses, net -60.1 -60.1 -59.4 -59.4 EBIT 813.3 -88.7 724.6 310.7 -111.2 199.5 Finance income 0.6 0.6 1.0 0.6 1.7 Finance costs -51.9 -96.2 -148.0 -48.5 -2.5 -51.0 Share of profit of associates 1.7 1.7 0.5 0.5 Profit before income taxes 763.7 -184.8 578.8 263.7 -113.1 150.6 Income tax expense -180.8 17.9 -162.9 -76.6 20.5 -56.0 Net profit for the period 582.9 -166.9 415.9 187.2 -92.6 94.6 Attributable to: Owners of the Company and hybrid capital investors 582.4 -166.9 415.5 187.1 -92.3 94.7 Non-controlling interests 0.4 0.4 0.1 -0.2 -0.1 Basic earnings per share (EUR) Total Attributable to owners of the Company Attributable to hybrid capital investors 3.05 -0.87 2.17 1.03 -0.51 0.52 2.97 -0.88 2.09 0.94 -0.52 0.43 0.08 0.01 0.09 0.09 0.01 0.09 Diluted earnings per share (EUR)1 Total Attributable to owners of the Company Attributable to hybrid capital investors 2.90 -0.83 2.07 0.98 -0.48 0.50 2.83 -0.84 1.99 0.90 -0.49 0.41 0.07 0.01 0.08 0.08 0.01 0.09 1 Following a ten-for-one stock split in November 2020, the figures for 2020 have been restated as if the stock split had been effective on 1 January, 2020. 89 88#90Consolidated Income Statement For the year ended 31 December 2020 * eurofins In millions of EUR Revenues Operating costs, net EBITDA Adjusted results 2020 Separately disclosed items 5,438.8 Reported results 5,438.8 Adjusted results 4,562.8 2019 Separately disclosed items Reported results 4,562.8 -4,026.1 -61.8 -4,087.9 -3,632.1 -97.8 -3,729.8 1,412.7 -61.8 1,350.8 930.7 -97.8 833.0 Depreciation and amortisation -389.1 -36.9 -426.0 -357.2 -38.7 -395.9 EBITAS 1,023.6 -98.7 924.9 573.5 -136.5 437.0 Share-based payment charge and acquisition-related expenses, net -124.5 -124.5 -70.5 -70.5 EBIT 1,023.6 -223.3 800.3 573.5 -206.9 366.6 Finance income 2.0 0.7 2.7 1.9 3.3 5.2 Finance costs -107.1 -3.3 -110.4 -98.8 -2.0 -100.9 Share of profit of associates 1.7 1.7 0.6 0.6 Profit before income taxes 920.2 -225.8 694.4 477.2 -205.6 271.5 Income tax expense -213.0 59.1 -153.9 -116.9 40.6 -76.3 Net profit for the year 707.2 -166.7 540.5 360.3 -165.0 195.3 Attributable to: Owners of the Company and hybrid capital investors 706.5 -167.0 539.4 359.4 -164.1 195.2 Non-controlling interests 0.7 0.3 1.0 0.9 -0.9 Basic earnings per share (EUR) - Total 3.79 -0.90 2.90 2.02 -0.92 1.10 - Attributable to owners of the Company 3.63 -0.91 2.71 1.75 -0.93 0.82 0.17 0.02 0.18 0.27 0.01 0.28 - Attributable to hybrid capital investors Diluted Earnings per share (EUR) - Total - Attributable to owners of the Company 3.61 -0.85 2.75 1.93 -0.88 1.05 3.45 -0.87 2.58 1.67 -0.89 0.78 - Attributable to hybrid capital investors 0.16 0.02 0.17 0.26 0.01 0.27 Basic weighted average shares outstanding - in millions 186.2 186.2 178.0 178.0 Diluted average shares outstanding - in millions 195.9 195.9 186.5 186.5 90 00#91Summarised Balance Sheet * eurofins In millions of EUR Property, plant and equipment Goodwill Other intangible assets 30 June 2021 1,667.3 1,574.9 3,643.3 3,524.1 31 December 2020 In millions of EUR Share capital Treasury shares Hybrid capital 30 June 2021 31 December 2020 1.9 1.9 1,000.0 1,000.0 814.9 825.1 Other reserves 1,555.2 1,542.6 Investments in associates Financial assets and other receivables Deferred tax assets Total non-current assets 6.9 5.6 Retained earnings 1,577.0 1,310.5 Currency translation reserve -54.9 -164.7 54.6 51.0 Total attributable to owners of the Company 4,079.2 3,690.3 61.1 76.6 Non-controlling interests 31.0 26.1 6,248.1 6,057.3 Total shareholders' equity 4,110.2 3,716.4 Borrowings 2,526.8 2,917.2 Inventories 169.1 157.0 Deferred tax liabilities 116.2 115.3 Trade receivables 978.3 948.5 Amounts due for business acquisitions 63.7 48.5 Contract assets 337.7 245.0 Employee benefit obligations 73.9 73.3 Prepaid expenses and other current assets Provisions 12.0 8.4 198.4 189.0 Total non-current liabilities 2,792.7 3,162.7 Current income tax assets 89.3 66.2 Derivative financial instruments assets 0.2 0.1 Borrowings 128.2 237.6 Cash and cash equivalents 639.9 912.4 Total current assets Total assets 2,412.9 2,518.2 Interest due on borrowings and earnings due on hybrid capital Trade accounts payable 44.4 51.3 530.8 542.0 Contract liabilities 162.9 136.7 8,661.0 8,575.5 Current income tax liabilities 123.0 84.3 Amounts due for business acquisitions 63.3 55.9 Provisions 26.3 36.3 Other current liabilities 679.1 552.3 Total current liabilities 1,758.1 1,696.4 Total liabilities and shareholders' equity 8,661.0 8,575.5 91#92Consolidated Balance Sheet * eurofins 31 31 31 31 In millions of EUR Property, plant and equipment Goodwill Other intangible assets December December 2020 2019 1,574.9 1,593.5 3,524.1 3,608.8 825.1 918.2 In millions of EUR Share capital Treasury Shares Hybrid capital December 2020 1.9 December 2019 1.8 -0.2 1,000.0 1,000.0 Investments in associates 5.6 5.3 Other reserves 1,542.6 978.2 Financial assets and other receivables 51.0 49.2 Retained earnings 1,310.5 718.9 Deferred tax assets 76.6 44.0 Currency translation reserve -164.7 139.8 Total non-current assets 6,057.3 6,218.9 Total attributable to owners of the Company 3,690.3 2,838.6 Non-controlling interests 26.1 59.5 Inventories 157.0 79.3 Total shareholders' equity 3,716.4 2,898.1 Trade receivables 948.5 810.7 Contract assets 245.0 190.5 Borrowings 2,917.2 3,086.9 Prepaid expenses and other current assets 189.0 153.0 Deferred tax liabilities 115.3 124.5 Current income tax assets 66.2 73.4 Amounts due for business acquisitions 48.5 51.7 Derivative financial instruments assets 0.1 0.3 Employee benefit obligations 73.3 75.3 Cash and cash equivalents 912.4 297.0 Provisions 8.4 5.1 Total current assets 2,518.2 1,604.1 Total non-current liabilities 3,162.7 3,343.4 Total assets 8,575.5 7,823.1 Borrowings 237.6 454.8 Interest due on borrowings and earnings due on hybrid 51.3 50.0 capital Trade accounts payable 542.0 409.8 Contract liabilities 136.7 116.4 Current income tax liabilities 84.3 20.7 Amounts due for business acquisitions 55.9 62.2 Provisions 36.3 22.0 Other current liabilities 552.3 445.6 Total current liabilities 1,696.4 1,581.6 Total liabilities and shareholders' equity 8,575.5 7,823.1 92#93Summarised Cash Flow Statement For the six months ended 30 June * eurofins In millions of EUR 2021 2020 Cash flows from operating activities Profit before income taxes 578.8 150.6 In millions of EUR Cash flows from financing activities Proceeds from issuance of share capital 2021 2020 12.6 544.6 Depreciation and amortisation 204.4 199.7 Proceeds from borrowings 742.7 595.3 Share-based payment charge and acquisition-related expenses, net 60.1 59.4 Repayments of borrowings -1,249.4 -924.3 Financial income/(expense), net 144.3 46.4 Repayments of lease liabilities -73.8 -75.1 Share of profit from associates -1.7 -0.5 Dividends paid to shareholders and non-controlling interests -0.4 Transactions costs and income related to acquisitions -3.8 -3.4 Earnings paid to hybrid capital investors -14.6 -14.6 Changes in provisions and employee benefit obligations -6.5 -2.7 Interest paid -135.8 -41.2 Other non-cash effects 0.4 -0.2 Net cash (used)/provided by financing activities -718.7 84.6 Change in net working capital Cash generated from operations Income taxes paid Net cash provided by operating activities Cash flows from investing activities -127.6 848.5 -139.9 708.6 13.4 462.7 Net effect of currency translation on cash and cash equivalents and bank overdrafts 14.7 -5.3 -17.7 Net (decrease)/increase in cash and cash equivalents and bank -271.9 319.0 overdrafts 445.0 Cash and cash equivalents and bank overdrafts at beginning of period Cash and cash equivalents and bank overdrafts at end of period 910.5 294.5 638.6 613.6 Purchase of property, plant and equipment Purchase, capitalisation of intangible assets Proceeds from sale of property, plant and equipment -200.1 -22.9 3.1 -113.0 -19.5 2.9 Net capex -219.8 -129.7 Free Cash Flow to the Firm 488.7 315.3 Acquisitions of subsidiaries net of cash acquired and proceeds from disposals -58.4 -76.4 of subsidiaries Disposals/(acquisition) of investments, financial assets and derivative financial 1.3 -0.5 instruments, net Interest received 0.5 1.2 Net cash used in investing activities -276.5 -205.3 93#94Consolidated Cash Flow Statement For the year ended 31 December 2020 * eurofins In millions of EUR 2020 2019 In millions of EUR 2020 2019 Cash flows from operating activities Cash flows from financing activities Profit before income taxes 694.4 271.5 Proceeds from issuance of share capital 564.8 23.4 Depreciation and amortisation 426.0 395.9 Proceeds from issuance of hybrid capital 297.6 Share-based payment charge and acquisition-related expenses, net 124.5 70.5 Proceeds from borrowings 946.2 192.2 Financial income and expense, net 101.8 96.1 Repayments of borrowings -1,304.5 -330.9 Share of profit from associates -1.7 -0.6 Repayment of lease liabilities -150.6 -142.4 Transactions costs and income related to acquisitions -6.2 -8.3 Repayment of hybrid capital -300.0 Changes in provisions and employee benefit obligations 18.7 7.3 Dividends paid to shareholders and non-controlling interests -0.5 -51.4 Other non-cash effects 8.5 4.6 Earnings paid to hybrid capital investors -36.3 -68.4 Change in net working capital Cash generated from operations Income taxes paid Net cash provided by operating activities Cash flows from investing activities Purchase of property, plant and equipment Purchase, capitalisation of intangible assets Proceeds from sale of property, plant and equipment Net capex Free Cash Flow to the Firm¹ -48.4 1,317.5 -94.0 1,223.5 -64.2 Interest paid -67.8 -62.7 772.9 Net cash provided by financing activities -48.6 -442.6 -95.0 677.9 Net effect of currency translation on cash and cash equivalents and bank overdrafts -33.9 4.1 -310.8 -44.7 5.2 -278.2 -44.3 3.2 Net increase (decrease) in cash equivalents and bank overdrafts Cash and cash equivalents and bank overdrafts at beginning of period Cash and cash equivalents and bank overdrafts at end of period 616.0 -200.5 294.5 495.0 910.5 294.5 -350.3 -319.3 873.2 358.6 Acquisition of subsidiaries net of cash acquired and proceeds -177.2 -171.0 from disposals of subsidiaries Acquisition and disposal in investments, financial assets and -0.1 47.6 derivative financial instrument, net Interest received 2.6 2.9 Net cash used in investing activities -525.0 -439.8 1Free Cash Flow to the Firm - Net cash provided by operating activities, less net capex. 94#95Contents ■ Executive Summary ■ Market & Strategic Positioning Financial review - ESG ■ Outlook ■ Summarised Financial Statements ■ Appendix eurofins 95#96* eurofins 45000% 40000% 35000% 30000% 25000% 20000% 15000% issue 1998 10000% €7m rights issue 5000% 1997 €6m IPO €5m 0% 27/10/1997 27/10/1998 27/10/1999 27/10/2000 CAC 40 *Source Marten & Co. study 24th October 2017 27/10/2001 27/10/200 27/10/2003 27/10/2004 27/10/2005 27/10/2006 Eurofins has vastly outperformed the market since its IPO (based on share price of €96.40 as of 30 June 2021) 55000% 50000% Eurofins: +52,595 % (30% 24-year CAGR) CAC 40: +135% (4% 24-year CAGR) SBF 120: +170% (4% 24-year CAGR) S&P 500: +390% (7% 24-year CAGR) Nasdaq: +846% (10% 24-year CAGR) 1999 2000 rights issue rights €38.5m Total equity raised in 8 offerings: only €1,387m €57m 1997-2000, €496m in 2016, €299m in 2017 and €535m in 2020 Best share price performance of all companies listed in Europe between IPO on October 1997 and October 10th 2017* Oct 2017 ABB** €299m Sept 2016 ABB** May 2020 ABB** €535m €296m June 2016 Private placement CDPQ €200m 27/10/2007 27/10/2008 SBF 120 S&P500 **ABB: Accelerated Book Building 27/10/2009 27/10/2010 27/10/2011 27/10/2012 Eurofins 27/10/2013 27/10/2014 27/10/2015 Nasdaq 27/10/2016 27/10/2017 27/10/2018 27/10/2019 27/10/2020 30/06/2021 96 96#97We have built a hard-to-replicate world-class infrastructure * eurofins Eurofins has been consistently investing more than its peers (average if more than 1 year) 12% 180% 160% 10% 140% Net Capex to Sales 8% 120% 100% 6% 80% 4% 60% 40% 2% 20% 0% 0% 00-'04 05-'09 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 I ERF ITICS ex ERF Excess investment Source: Eurofins, Company websites. TICS ex ERF = SGS, Intertek, Bureau Veritas 97#98Eurofins has been allocating a significant part of its free cash flow to equity towards building its leading global platform eurofins Figures in €m 1,200 1,000 800 600 400 200 0 2015 Cashflow expansion levers: cash investments impacting cashflows 2016 2017 2018 2019 FCF invested for the future (SDIs) €121m* Reported FCF to the Firm ** ■Start-ups (operating losses) and reorganization costs (EBITDA level) ■Extra capex above requirements for normal growth level (above 6% of revenues excl. IFRS 16) Reported FCF to the Firm *€92m estimated cyber-attack cost & cash flow impact, €29m for purchase of 2 buildings at year-end **Reported Free Cash Flow to the Firm - Net cash provided by operating activities, less Net capex 2020 98#99Start-ups expected to break-even on Year 3 and typically reach Group's profitability objectives in the following years Illustration: Example of a typical Eurofins' start-up Start-up A Revenue Dynamic growth Start-ups development: 1) 2) 3) * eurofins Large investments have short-term dilutive impact on Group's margins and FCF Growth momentum allows start-ups to typically break-even on Year 3 post-creation From year 5 ROCE generally better than growth via acquisitions Total Cumulative CAPEX Year 1 Year 2 Year 3 Year 4 Year 5 Pre-accreditation: Receiving Establishing accreditation infrastructure Year 1 Year 2 Year 3 Year 4 Year 5 I EBITDA Break-even achieved Year 1 Year 2 Year 3 Year 4 Year 5 Start-up reaches Developing towards break-even Group's profitability levels 99#100Shareholder Returns: TICS & Clinical Diagnostics Companies * eurofins Shareholder Returns (based on share prices as of close 31.12.2020 in %) Based on share prices Total Shareholder Returns (Assumes all dividends re-invested) Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 Dec-18 Dec-19 Dec-20 Dec-11 Dec-12 Dec-13 Dec-14 Dec-15 Dec-16 Dec-17 Dec-18 Dec-19 Dec-20 100.0 217.5 348.8 376.4 571.4 719.0 901.1 578.7 877.3 1,218.4 100.0 219.5 354.4 384.6 586.6 741.4 933.0 602.2 919.5 1,276.9 100.0 130.3 132.0 131.5 122.9 133.2 163.4 142.1 170.5 171.7 100.0 135.3 140.4 144.3 139.7 156.6 198.5 178.1 220.4 229.7 100.0 152.3 154.7 114.7 136.5 171.1 255.0 235.9 287.6 277.5 100.0 154.3 158.8 119.8 145.3 185.1 280.2 263.3 327.3 322.0 100.0 150.4 150.9 130.1 130.7 130.8 162.7 126.4 165.3 154.6 100.0 153.1 156.9 138.3 142.2 146.1 185.7 148.9 199.7 186.8 100.0 110.2 91.2 55.6 41.3 66.2 76.6 74.3 100.6 105.3 100.0 115.6 100.7 64.3 49.5 80.9 99.6 99.5 139.4 149.4 100.0 100.4 92.2 115.5 122.5 158.3 169.6 143.4 183.9 205.3 100.0 101.5 95.2 121.9 132.0 174.1 190.1 163.8 214.8 245.0 100.0 118.2 147.0 164.0 158.4 189.7 202.7 196.0 254.9 285.0 100.0 123.9 160.7 186.4 186.5 231.6 267.1 267.7 360.6 415.7 100.0 137.1 194.1 232.9 294.1 278.8 400.5 414.1 558.9 914.2 100.0 137.1 194.1 232.9 294.1 278.8 400.5 414.1 558.9 914.2 100.0 147.9 223.7 242.8 276.7 323.1 402.5 372.1 426.0 517.6 100.0 147.9 223.7 242.8 276.7 323.1 402.5 372.1 426.0 517.6 100.0 98.2 172.2 203.9 205.1 189.8 100.0 61.4 30.0 80.6 100.0 98.2 172.2 203.9 205.1 189.8 100.0 61.4 30.0 80.6 100.0 100.8 106.3 125.5 143.8 149.3 185.5 147.0 196.8 236.8 100.0 100.8 106.3 125.5 143.8 149.3 185.5 147.0 196.8 236.8 100.0 120.6 138.2 192.7 189.5 304.8 406.4 483.4 678.6 1,299.0 100.0 120.6 138.2 192.7 189.5 304.8 406.4 483.4 678.6 1,299.0 100.0 105.8 121.1 117.8 112.0 128.2 138.0 120.7 135.4 115.9 100.0 110.0 130.5 131.5 129.7 154.5 173.0 157.8 185.0 163.8 100.0 129.1 161.9 166.2 182.1 194.6 219.0 179.0 224.6 232.6 100.0 129.1 161.9 166.2 182.1 194.6 219.0 179.0 224.6 232.6 100.0 113.4 147.0 163.7 162.5 178.0 212.6 199.3 256.9 298.7 100.0 116.0 153.5 174.5 176.9 198.1 241.3 230.7 303.4 359.1 100.0 115.2 136.0 135.2 146.8 153.9 169.0 149.7 189.2 175.7 100.0 120.4 147.1 150.8 168.9 183.7 206.8 190.0 247.8 235.5 Share price evolution 2011-2020 Total Shareholder Returns 2011-2020 (Assumes all dividends re-invested) 1400.0% 1200.0% 1000.0% 800.0% 600.0% 400.0% 200.0% 0.0% 12/11 1400% Eurofins 1200% 1000% 800% 600% 400% 200% 0% 12/12 12/13 12/14 12/15 12/16 12/17 12/18 12/19 12/20 12/11 ERF FP Equity SGSN SW Equity ITRK LN Equity BVI FP Equity ALQ AU Equity DGX US Equity SHL AU Equity CRL US Equity NEOG US Equity UKX Index OPK US Equity LH US Equity DAX Index - SPX Index IDXX US Equity CAC Index NEOG US Equity UKX Index Source: Bloomberg Eurofins 12/12 12/13 12/14 12/15 12/16 12/17 12/18 12/19 12/20 ERF FP Equity SGSN SW Equity ITRK LN Equity ALQ AU Equity DGX US Equity SHL AU Equity BVI FP Equity CRL US Equity OPK US Equity DAX Index LH US Equity SPX Index IDXX US Equity CAC Index 100#101Shareholder Returns: TICS & Clinical Diagnostics Companies Historical Share Price Development (Y vs Y-1) * eurofins Compounded Annual Growth Rates 2 Y 3Y 4 Y 5Y 5Y 2018- 2017- 2016- 2015- Dec-13 Dec-14 Dec-15 Eurofins SGS Intertek BV ALS Quest Diagnostics Sonic Healthcare Charles River Neogen Opko Labcorp 5.5% 18.1% 60.4% 7.9% 51.8% 1.3% -0.3% -6.6% 1.6% -25.9% 19.0% 0.4% -13.8% 0.4% -17.2% -39.0% -25.7% -8.1% 25.3% 6.1% 24.4% 11.6% -3.4% 41.6% 20.0% 26.3% 51.3% 8.5% 14.0% 75.5% 18.4% 0.6% 14.6% Idexx 14.6% 39.4% -1.6% 60.8% FTSE100 14.4% -2.7% -4.9% 14.4% DAX 25.5% 2.7% 9.6% S&P500 29.6% 11.4% -0.7% CAC40 18.0% -0.5% 8.5% 40.4% 7.6% -12.5% 12.1% 6.9% 12.5% -18.3% 25.5% 9.5% 19.4% -6.2% 28.9% 4.9% 9.8% -11.4% 24.2% -20.8% 33.9% 33.4% 19.0% Dec-16 Dec-17 Dec-18 Dec-19 Dec-20 Growth 25.8% 25.3% -35.8% 51.6% 38.9% 113.2% 8.4% 22.6% -13.0% 20.0% 0.7% 25.4% 49.1% -7.5% 21.9% -3.5% 103.4% 0.1% 24.4% -22.3% 30.7% -6.4% 60.2% 15.7% -3.0% 35.4% 4.7% 29.2% 7.2% -15.5% 28.2% 11.6% 19.8% 6.8% -3.3% 30.0% 11.8% -5.2% 43.7% 3.4% 35.0% 63.6% 16.8% 24.6% -7.6% 14.5% 21.5% -7.5% -47.3% -38.6% -51.2% 168.7% 3.8% 2020 2020 2020 2020 45% 11% 14% 16% 39.7% 10% 2% 7% 7% 8% 3% 13% 15% 18.3% 11% -2% 4% 3% 154.9% 19% 11% 12% 21% 67.5% 20% 7% 7% 11% 79.9% 21% 12% 11% 12% 210.8% 49% 32% 35% 25% 87.1% 18% 9% 13% 13% -60.7% 15% -7% -19% -17% 20.3% 64.6% 27% 8% 12% 10% 91.4% -14.3% 585.5% 64% 47% 44% 47% 3.5% -2% -6% -2% 1% 3.5% 27.7% 14% 2% 5% 5% 16.3% 83.8% 22% 12% 14% 13% 26.4% -7.1% 19.7% 8% 1% 3% 4% Source: Bloomberg Based on share prices at close of 31 December of each year Long term (since IPO) Eurofins performance track record (Compounded Annual Growth Rates) 23Y CAGR IPO 27/10/1997 - Eurofins Outperformance Factor 31/12/2020 Eurofins 29.4% FTSE100 1.3% 23.3x DAX 5.6% 5.2x S&P500 6.5% 4.5x CAC40 3.1% 9.6x Source: Bloomberg 101#102Definitions/Alternative Performance Measures (APMs) eurofins Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results - reflect the ongoing performance of the mature and recurring activities excluding "separately disclosed items". Separately disclosed items - include one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, share-based payment charges, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, gains/losses on disposal of businesses and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions, net finance costs related to borrowing and investing excess cash and one-off financial effects (net of finance income) and the related tax effects EBITDA - Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions. EBITAS - EBITDA less depreciation and amortisation. Share-based payment charge and acquisition-related expenses, net - Share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions. EBIT EBITAS less Share-based payment charge and acquisition-related expenses. APMs used in the Interim Condensed Consolidated Cash flow Statement Net capex-Acquisition of intangible assets, property, plant and equipment, less proceeds from the disposal of such assets Free Cash Flow to the Firm - Net cash provided by operating activities, less Net capex. APMs used in the Notes Net debt - Borrowings, less cash and cash equivalents. Net working capital - Inventories, trade receivables and contract assets, prepaid expenses and other current assets less trade accounts payable, contract liabilities and other current liabilities excluding accrued interest receivable and payable. 102